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ABSTRACT
Key Words: Competitive advantage, Competitiveness, Cost of Quality, GMP, ISO, 
Quality Improvement, Quality Management Systems, Regulations, Standards.
The  pharmaceutical  industry  is  one  of  the  most  important  sectors  because 
pharmaceutical  products are used for human health.  So, this sector is in general, 
heavily regulated to ensure that they are fit for their intended use, comply with the 
requirements and do not place patients at risk due to inadequate safety, quality or 
efficacy.  The  attainment  of  this  quality  objective  is  the  responsibility  of  senior 
management  and  requires  the  participation  and  commitment  by  staff  in  many 
different  departments  and  at  all  levels  within  the  company,  by  the  company’s 
suppliers and by the distributors. To achieve the quality objective reliably there must 
be  a  comprehensively  designed  and  correctly  implemented  system  of  Quality 
Assurance incorporating Good Manufacturing Practice and thus Quality Control.
  There is a sever competition in the pharmaceutical industry all over the world, and 
there is  increasing of costs related to production,  research and development,  etc. 
Like, other markets all over the world, there is sever pharmaceutical competition in 
Palestinian market. There are three types of companies competing in the Palestinian 
market  regarding  to  their  origin,  Palestinian  companies,  Israeli  companies,  and 
International companies.  
  Palestinian pharmaceutical companies face many challenges, such as, competition 
between  each  others,  competition  with  Israeli  companies,  and  with  International 
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companies,  complying  with  international  standards  and  regulations,  and  cost 
reduction.
  Palestinian pharmaceutical companies started focusing and working to comply with 
and to  produce  according  to  international  regulations  such as,  FDA-cGMP, EU- 
GMP, and WHO- GMP since the beginning of 1990s. So, they started to invest in 
improving  quality,  in  order  to  face  the  local  competition  and  to  seek  for 
opportunities for exporting their  products. They have implemented ISO9000, and 
ISO  14000,  and  they  are  trying  to  get  the  certificate  of  Good  Manufacturing 
Practices (GMP). 
 The  purpose  of  this  study  was  to  investigate  the  pharmaceutical  companies' 
commitment  to  improving  quality,  to  investigate  the  correlation  between  quality 
management  systems and cost,  and to investigate  the correlation between quality 
management systems and competitiveness. 
The study used various methods to collect the data and test the hypotheses, such as 
the literature review, the questionnaire, and interviews. The results proved that there 
is  commitment  for  improving  quality,  in  order  to  face  competition  in  the  local 
market and compete globally, after getting GMP certificate.
Moreover, the study showed that a correlation exists between quality improvement 
and  cost  reduction,  and,  it  showed  that  correlation  exists  between  quality  and 
competitiveness. 
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ملخص
   يعتبر قطاع الصناعات الدوائية من القطاعات الهامة, لنه يعنى بصحة النسان. و بالتالي, فان هذا القطاع
 يعتبر, عموما, من القطاعات الخاضعة للرقابة للتأكد من أن المنتج الدوائي مناسب و مطابق للمعايير و ل
 يتسبب بأي خطورة على المريض المستخدم نتيجة لخلل في أمانه, جودته, و فعاليته. إن مسؤولية تحقيق أهداف
 جودة الدوية تقع على الدارة العليا للشركة المنتجة كما تتطلب مشاركة و التزام الموظفين من مختلف
 المستويات و القسام. و لتحقيق ثباتية أهداف الجودة ل بد من تصميم شامل و تطبيق دقيق لنظام تأكيد الجودة
بالتوازي مع نظام التصنيع الجيد و نظام ضبط الجودة.
    المنافسة شديدة في أسواق الدواء على مستوى العام, كما إن هناك زيادة في التكاليف ذات الصلة بالنتاج و
البحث و التطوير و غيره. 
   كما هو الحال في السواق العالمية, فان سوق الدواء الفلسطيني يشهد أيضا منافسة شديدة. حيث هناك ثلثة
 أنواع من الشركات المتنافسة في السوق الفلسطيني, اعتمادا على مصدر الشركة, الشركات الفلسطينية,
الشركات السرائيلية, و الشركات الجنبية أو العالمية.
   إن شركات الدوية الفلسطينية تواجه العديد من التحديات, مثل المنافسة بين هذه الشركات مع بعضها, منافسة
 الشركات السرائيلية و العالمية, العمل بناء على المواصفات العالمية, و تقليل التكاليف. في مطلع التسعينات من
 القرن الماضي, بدأت الشركات الفلسطينية تركز و تعمل على النتاج بناءا على المواصفات و المتطلبات
 العالمية في التصنيع الدوائي مثل نظام التصنيع الجيد الصادر عن مؤسسة الغذاء و الدواء المريكية, التحاد
 الوروبي أو منظمة الصحة العالمية. و بالتالي فإنهم بدءوا الستثمار في تحسين الجودة لمواجهة المنافسة
المحلية و للتحسين فرص تصدير منتجاتهم للخارج.
 , كما إنها تحاول الحصول على شهادة00041 OSI و 0009 OSI  إن الشركات الفلسطينية طبقت نظام 
(.PMGالتصنيع الجيد )
   الهدف من هذه الدراسة هو التحقق من مدى التزام شركات الدوية الفلسطينية في تحسين الجودة,  هل يوجد
علقة بين تحسين الجودة و التكاليف وهل يوجد علقة بين تحسين الجودة و التنافسية.
iiix
 لقد تم استخدام عدة طرق لجمع البيانات و فحص الفرضيات, مثل مراجعة الدراسات السابقة بهذا المجال,
استخدام الستبيان و المقابلت, بالضافة إلى فحص الفرضيات بواسطة الطرق الحصائية اللزمة. 
     لقد أظهرت الدراسة أن هناك التزام من الشركات نحو تحسين الجودة لمواجهة المنافسة المحلية, و للقدرة
 على التنافس في السواق العالمية في حال حصلت هذه الشركات على شهادة المواصفات العالمية. كما أن
 الدراسة أثبتت وجود علقة بين تحسين الجودة و تقليل التكاليف, و وجود علقة بين تحسين الجودة و زيادة
الميزة التنافسية.
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CHAPTER ONE
Introduction
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1.1 Overview  
 Improving quality has been found to be a wonderful tonic for improving operations 
for many firms. To build successful strategies of differentiation, least cost, and rapid 
response,  firms  need  to  implement  effective  quality  management  systems. 
Implementing an effective quality management system is an integrated process that 
can help a  firm to produce differentiated  products  at  a  high quality  to  meet  the 
customer quality expectations,  rapidly respond to customer orders, and achieving 
efficient productivity at the lowest possible costs. By achieving differentiation, rapid 
response,  and  costs  reduction  through  developing  efficient  process  to  produce 
consistent  quality  products,  sales  and profitability  will  increase.  De Feo,  (2003) 
classified quality's evolution into three periods. First was the industrial revolution, 
which led to higher quality and higher costs. Then mass production era, a period 
ending well past World War II, when there was moderate quality and lower costs. 
And now, there is a new era, organizations will create high quality at lowest costs.
In summary,  quality means understanding and optimizing  the system so that  the 
whole  process  continues  to  operate  and  optimize  the  whole  system  of  value 
exchange (Straker, 2001). This means that the definition of quality is related to the 
product and/ or service and the process and the definition includes requirements and 
standards, management commitment, customer focus, investment in employees and 
involving them in the quality process, and operating at minimal cost.
  Quality is never an accident.  It  is always  the result  of  high intentions,  sincere 
efforts, intelligent direction and skillful execution. It is an attribute or characteristic 
whose dictionary meaning is the degree of goodness or worth of a person, place or 
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thing,  (Kaul,  2004).
In  determining  the  quality  of  a  product,  the  customer's  expectations  about  the 
product will be given the top most priority. In the present scenario, customer delight 
is  the  need  of  the  hour  in  order  to  survive  the  cutthroat  competition.
Kaul, (2004), mentioned that in this age of liberalization the quality of products has 
become  a  major  concern  for  pharmaceutical  industries.  To  be  competitive,  an 
industry needs to provide a product/service,  into which quality is designed, built, 
marketed and maintained at the most economical  cost,  which brings in customer 
"delight"  instead  of  customer  satisfaction.  These  competitive  edges  made  the 
pharmaceutical industries think of approaching quality management efforts in their 
total form, known as Total Quality Management. 
 Quality management is the application of a formalized system to achieve maximum 
customer satisfaction at the lowest overall cost to the organization while continuing 
to  improve.  A  formal  quality  management  system  documents  the  structure, 
responsibilities, and procedures required to manage and improve quality effectively 
(ASQ).  As stated by Nichols,  (2002); Gilmour  and Hunt,  (1995) mentioned that 
quality is described as a concept rather than a technique, so its implementation is 
very much  dependent  on the  type  of  organization  or  process  at  hand.   Deming, 
(1994);  Gilmour  and  Hunt,  (1995)  concluded  that  identifying  processes  is  an 
important step toward improving them and predicting the consequences of changes; 
process maps should consider all aspects of the service including suppliers, clients, 
design, production, and delivery .The job of quality management is not just advising 
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a sampling plan for the acceptance/ rejection of the incoming materials or products 
and controlling manufacturing process conditions.  
Management commitment for improving quality is one of the most important factors 
for continuous improvement.  The management commitment  can be clear  through 
conducting quality policies as main part of quality management systems. Quality 
policies  play an important  role  in  the understanding  of  a  company’s  operational 
principles  and  practices.  The  most  successful  policy  implementation  in  the 
companies studied relied on policies being drafted internally with the cooperation of 
not  only the  nominated  quality  management  but  also  the  supporting  non-quality 
management functions. The use of a structured and predetermined implementation 
plan  that  is  shared  across  all  sectors  of  the  company  and  the  development  of 
supporting  systems  to  monitor  progress  were  also observed to  benefit  employee 
involvement and effective policies, (London, 2005)
Quality Management is a company wide activity, involving the combined efforts of 
various  departments  such  as  R & D,  engineering,  purchase,  production,  Quality 
Control,  Quality  Assurance,  Human  Resources,  Marketing,  Distribution, 
Warehouse, etc in different phases with a view to achieve the desired quality of the 
end product.
Implementation  of  a  comprehensive  quality  systems  model  for human 
pharmaceutical  products  will  facilitate  compliance  with  Good  Manufacturing 
Practices  (GMP).  The  central  goal  of  a  quality  system  is  to  ensure  consistent 
production of safe and effective products and that these activities are sustainable.  
Quality  professionals  are  aware  that  good intentions  alone  will  not  ensure  good 
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products.  A robust quality system will promote process consistency by integrating 
effective  knowledge-building  mechanisms  into daily  operational  decisions.  When 
fully developed and effectively managed, a quality system will lead to consistent, 
predictable  processes  that  ensure  that  pharmaceuticals  are  safe,  effective,  and 
available for the consumer.
1.1.1 Costs and Benefits of Quality
  Improving  quality  requires  adding  certain  amount  of  effort  and  cost,  so  it  is 
essential for every industrial company to know the cost of quality. However, these 
incremental costs are supposed to be rewarded with increased benefits and reduced 
costs throughout the life cycle of the solution. Like all things there is a price to pay 
for quality, so, it costs money and time to build a quality solution; but the benefits of 
quality improvement can exceed these costs.  Consider leaving the quality steps out 
in order to save money; then you will have to deal with direct and indirect costs of 
poor quality. These costs may not be apparent when the project is progressing, but 
should definitely  be taken into  account  as  part  of  the  full  life  cycle  cost  of  the 
solution being delivered. The costs of quality must be weighed against the benefits 
of providing a quality solution. Whereas many of the costs of quality show up in the 
project,  many of the benefits of quality show up over the entire life cycle of the 
solution.  In  recent  years,  many  companies  have  recognized  the  important 
relationship between cost and quality,  unlike the past,  when companies generally 
underestimated the costs of poor quality because they were difficult to quantify.
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As stated by Omachonu and Ross, (1994); Garvin (1988) mentioned that there are 
three views of quality costs:
1- Higher quality means higher cost. This is due to the belief that improving 
quality adds costs in labor, material, design, and other costly resources and 
these extra costs are not compensated by additional benefits.
2- The cost of improving quality is less than the resulting savings. This means 
that  the savings result  from less rework,  scrap,  and other direct  expenses 
related to defects  are more than the cost  of improvement.  This view was 
originally  promoted  by  Deming  and  is  widely  held  among  Japanese 
manufacturers.
3- Quality costs  are  those incurred in excess of those that  would have been 
incurred if the product was built or the service was performed exactly right 
the first time. This view represents the TQM philosophy and this means that 
costs are not only include direct costs, but they also, include those resulting 
from  lost  customers,  lost  market  share,  and  the  many  hidden  costs  and 
foregone opportunities not identified by cost accounting systems.    
  The cost of quality is not a new concept and there are a lot of pioneers who tried to 
focus on this  concept.  Feingenbaum, (1961) developed the prevention-  appraisal- 
failure (PAF) model. The model classifies the cost of quality into three categories:
1. Cost of Prevention: the cost of any action taken to investigate, prevent or reduce 
the risk of non- conformity or defects.
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2.  Cost  of  Appraisal:  The  costs  of  evaluating  the  achievement  of  quality 
requirements.
3. Cost of Failure: The costs of non- conformance, both external and internal failure.
Zairi,  (1997),  mentioned that  both Rank Xerox and Lea  Ronal  (UK) added two 
additional elements to the (PAF) model:
1. The  cost  of  exceeding  requirements:  The  costs  incurred  to  provide 
information or services which are unnecessary or unimportant or of which no 
agreed requirements have been established.
2. Cost of opportunities lost: The loss of profits resulting from changing the 
customer  purchase  attitude  to  buy  competitors'  products  or  cancellation 
products or services that didn't meet customer requirements. 
  As mentioned by Chen and Yang, (2002); Grosby, (1984), classified total costs of 
quality (COQ) into two broad categories: 
1. Poor quality or Non Conformance: This area covers the price paid by not having 
quality systems or a quality product or costs incurred because of defective quality 
problems occurring on the first run. Examples of this are:   
(1) Rework: Doing the job over again because it wasn't right the first time. 
(2)  Scrap:  Throwing away the  results  of  your  work  because  it  is  not  up  to  the 
required standard. 
(3) Waiting: Time wasted while waiting for other people. 
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(4) Down Time: Not being able to do your job because a machine is broken.
(5) Client  dissatisfaction:   defects  mean that the client  will  be more dissatisfied. 
Lower service quality will also make the client experience less pleasure, which will 
result in more complaints and may translate into decreasing sales.
(6) Poor Moral:  No one likes to work for an organization or a project that has poor 
processes or produces poor quality solutions. Costs of poor morale include increased 
absenteeism, higher turnover and less productivity from the staff
1.  Cost of Conformance: Conformance is an aim of quality assurance. This aim 
is  achieved  at  a  price,  which  includes  the  costs  of  ensuring  that  goods  are 
produced defect free. Examples of this are: 
(1) Documentation:  Writing work instructions, technical instructions and producing 
paperwork. 
(2) Training: On the job training, quality training, etc. 
(3) Auditing: Internal, external and extrinsic. 
(4) Planning: Prevention, do the right thing on the first time. 
(5) Inspection: Vehicles, equipment, buildings and people.
(6) Testing: Testing is a part of the project life cycle, but it is also done to ensure the 
solution meets requirements and quality standards. 
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  It is clear that no one will deny the importance of quality, but there is confusion in 
the trade off and pay off between cost and quality. To provide value for money, it is 
necessary  for  companies  to  measure  and  control  all  quality  costs  related  to 
production, by establishing a quality cost system. By using this system, the company 
can  collect  costs  across  the  whole lifecycle  of  the  product  or  service  to  include 
consumer and operational failure costs. When the total costs of  having poor quality 
is  realized  by  management,  it  is  easy  for  the  company  to  make  a  comparison 
between cost of improving quality and cost of  having poor quality, which leads to 
better allocation of resources specially in the man power, machine,  methods, and 
materials.  According  to  Omachonu  and  Ross,  (1994),   by  implementing  cost  of 
quality systems, Hewelett- Packard could estimate that the cost of not doing things 
right the first time was 25 to 30 percent of revenues, and Motorola has reduced the 
cost of poor quality by about 5 percent of total sales or about $480 million per year. 
  There is a trend of an increased focus on quality to satisfy customers and to achieve 
efficacy and effectiveness, which costs money. The raised question is "Are quality-
related  efforts  worth  their  cost?  In  other  words,  what  is  quality's  return  on 
investment?" 
  To answer this question, a relationship must exist between quality and financial 
results  and the quality  costs  and results  must  be measurable  in terms of money. 
According to Leung, Chan, and Lee, (1999) there are many benefits or results of 
quality management system such as ISO 9000, which can be measurable as benefits 
for  staff,  operation  and  business,  and  these  benefits  lead  to  productivity 
improvement, competitiveness improvement, and cost reduction, as summarized in 
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Table  (1).   So,  savings  (improved  productivity,  lower  costs,  short  duration,  low 
defects, and team moral),  revenues (client satisfaction and Competitiveness)  and 
reducing  cost  of  poor  quality  resulted  from  achieving  high  quality  may  be 
reasonable enough to cover cost of quality and generate more profits.
Table (1); Benefits of quality management systems on staff, operation and business.
Benefits to staff Benefits to operation Benefits to business entity
Clearer working 
procedures
Shorter delivery lead time Attracted more new local 
customers
Improved team spirit Reduced wastage of 
materials 
Increased sales with 
existing customers
Less staff conflicts Increased efficiency Received less complaints
Lower staff turnover rate Improved quality of product/ 
service
Increased profits 
Received more 
suggestions from staff
- Acquired a better 
control of 
subcontractors
- Reduced operational 
costs
- Increased quantity of 
production
- Attracted more new 
overseas
customers
- Customers exercised less
control on your process
Adapted from Leung, Chan, and Lee, (1999)
To assess the effect  of quality on financial  results,  Heinloth, (2000), suggested a 
simple  economic  equation  (Profit  =  Income  –  Expenses)  to  investigate  the 
correlation of good quality and poor quality on income and expenses, which means 
that if benefits of quality were measured in financial language, the organization can 
measure or investigate the cost and benefit of quality. However, Corbett, Montes-
Sancho,  and  Kirsch,  (2004)  concluded  that  the  degree  of  obtaining  benefits  of 
quality management system differs from firm to another, and firms implementing 
the standard in a more rigorous and comprehensive way than others,  are likely to 
obtain  more  benefits. Finally,  they  generalized  that  careful  design  and 
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implementation  of  consistent  and  documented  quality  management  systems  can 
contribute significantly to superior financial performance. 
More managers  than ever  before are  focusing on quality  as a  way of increasing 
productivity,  reducing  costs,  and  meeting  customer  needs.   These  managers  are 
beginning to understand the importance of continuously improving the quality of 
their services and products as a way of achieving these goals, (Suarez, 1992). 
   As mentioned before, pharmaceutical industry is highly regulated to insure safety 
and efficacy.  Regulation  of  safety,  efficacy and quality  fundamentally  affect  the 
industry’s cost structure and the nature of competition,  while regulation of price, 
reimbursement and promotion affect demand and profitability. Adopted regulations 
have been and remain a critical factor that shape this industry and must be central to 
any  realistic  analysis  of  the  industry.  Regulatory  control  may  also  benefit 
consumers, by reducing the risk that harmful or useless drugs are admitted to the 
market. The production of safety and efficacy information is a public good which 
may be underprovided by the market. For safety, liability may provide an alternative 
corrective to regulation. For efficacy, the market may acquire information over time, 
but learning by experience may entail a welfare loss. The optimal regulatory policy 
would set safety and efficacy standards to achieve the optimal balance between costs 
and benefits, (Danzon, 1999).
1.1.2 Impact of Quality on competitiveness
Customer satisfaction with a company’s products or services is often seen as the key 
to  a  company’s  success  and  long-term competitiveness.  Quality  improvement  is 
11
important as integral to do a business the smart way leading to customer satisfaction. 
To  drive  responsibility  for  the  quality  process  through  the  ranks  of  your 
organization,  you should assess individual  contributions  to the quality process as 
part of every employee's  periodic review.  There is a direct relationship between 
value and  competition. A fundamental rule in crafting a competitive strategy is to 
view  competition  from  the  other  player's  viewpoints.  The  firm  must  become 
competitor-oriented to be successful and to be able to survive. You must pursue the 
right  competitive strategy - avoid strengths of your competitors and look for weak 
points in their positions and then launch marketing attacks against those weak points. 
Berawi,  (2004),  stated  that  why and  how the  company  makes  progress  towards 
higher  level  of  quality  is  intangible  assets  optimization,  and  companies  need 
superior quality to face global competition.
  As mentioned by Talha, (2004), the American Society for Quality Control defines 
quality as "the total  features and characteristics of a product or service made or 
performed according to specifications to satisfy customers at the time of purchase 
and during use". Many companies throughout the world have emphasized quality as 
an  important  strategic  dimension  because  a  quality  focus  reduces  costs  and 
increases customer satisfaction (Talha, 2004). 
  Customer  satisfaction  is  considered  as  an  important  principle  of  quality.  This 
means  that  improving  quality  can satisfy customers  leading  to  good reputations, 
sales increase, and increase the profitability.  So, the key to competitive advantage 
lies in continuously satisfying customers’ needs. 
To begin an effective quality management system start-up, management must first 
decide on exactly what their definition of quality is and where they want to go with 
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it. Where to begin is also a concern. Implementing TQM provides benefits in both 
internal  and  external  measures.  Waste  reduction,  lowered  costs  of  quality  or 
improvement  in  time  and  operation  of  the  processes  are  internals.  The  external 
relationships  of  the  organization:  customer  satisfaction,  suppliers’  satisfaction  or 
increased sales (Escrig-Tena, 2003).
Understanding customer perceptions is essential  to remain competitive nowadays. 
To do this, a company should not only know the customer satisfaction degree to its 
current product or service, but also know the customer satisfaction degree to the 
competitors.
Based on the customer satisfaction degree to both the company and competitors’ 
products,  a  goal  is  to  be decided  to  show the  target  for  meeting  each  customer 
attribute. The goal combines the data describing the customers’ perception of the 
competitive  position  of  the  product  or  service  relative  to  its  competitors.  The 
customer  satisfaction  degree  is  the  customers’  rating  according  to  the  current 
product, while the goal is the future-state rating to be reached. The goal is to put 
customer satisfaction benchmarking to work for the company to achieve world-class 
competitive capability. 
   In the pharmaceutical industry today, as with many other industries, demands for 
quality have never been higher. The pharmaceutical industry is in an increasingly 
complex and dynamic environment. There have been a lot of changes in recent years 
in the pharmaceutical industry and this trend is likely to continue. In global market, 
pharmaceutical  companies  must  meet  many  new  challenges  to  ensure  efficient 
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business operations. There are external challenges from competitors, generic drug 
manufacturers,  health-care  organizations,  in  addition  to  internal  challenges  to 
decrease the costs of sales, R&D, and manufacturing. Competition and technological 
advances have increased levels of uncertainty (McAdam, and Barron, 2002). Bashe, 
(2000),  stated  that  the  increase  in  consumer  power  will  fundamentally  force 
pharmaceutical companies to change the way they do business. For these reasons, 
Quality  is  now the  major  differentiator  in  this  increasingly  competitive  business 
environment.
   Palestinian pharmaceutical companies have similar challenges, and they also have 
their unique situation and challenges such as, competition of Israeli companies and 
international  companies,  they are  all  producing generics   (they don’t  develop or 
innovate  new  products),  they  are  selling  locally  only  (some  exceptions)  which 
increase  the severity  of  competition,  and  finally,   customers'  perception,   which 
means that customers believe that the Palestinian pharmaceutical products, like all 
other locally produced items have less quality than Israeli or foreign products, which 
affects  their  competitiveness.  The  customers'  perception  toward  Palestinian 
pharmaceutical products was investigated through some studies like Massar, 1997, 
and Massar, 2000. 
1.2 Purpose of the Study:   
     The purpose of this study is to investigate the management commitment for 
improving quality in Palestinian Pharmaceutical Companies and to investigate 
the  correlation  between  improving  quality  through  implementing  effective 
quality management systems, such as ISO 9000 and ISO 14000, and complying 
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with  the  international  regulations,  such  as  cGMP  and  cost  and/  or 
competitiveness.
1.3 Problem Statement:  
1.3.1 The Problem Statement of the study is: 
To  what  extent  managements  are  committed  to  improve  quality  of  Palestinian  
Pharmaceuticals?  What  is  the  correlation  between effective  quality  management  
systems implementation,  Cost, and competitiveness in Palestinian pharmaceutical  
companies?
1.3.2 Justifications of selecting the problem statement:
Demand for quality is now higher than before and it is now the major differentiator 
in  the  current  increasingly  competitive  business.  Pharmaceutical  companies  are 
working in sever competitive business and they must meet many challenges, such as 
competition and reducing costs, to ensure efficient business operations (McAdam 
and Barron, 2002). 
 Today, pharmaceutical companies are working hardly to minimize costs, increase 
productivity  and  maintain  a  high  level  of  quality  and  regulatory  compliance. 
Pharmaceutical products are directed to satisfy consumer needs in there health care 
which is vital for society. 
Minimizing  costs,  increasing  productivity,  achieving  customer  satisfaction,  and 
maintaining high level of quality are challenges for pharmaceutical companies. 
  According to Kaul, (2004), the top most priority of determining the quality of a 
product is the customer's expectation about the product, and the customer delight is 
the need to survive and to effectively compete.  To delight customers and to face 
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competition, the quality of products has become a major concern for pharmaceutical 
industries. Pharmaceutical industries need to provide products, into which quality is 
designed, built, marketed and maintained at the most economical cost, which brings 
in customer "delight" instead of customer satisfaction and they started to think of 
approaching quality management efforts in their total form. So, the study tries to 
answer the following questions:
- Is there a commitment to improve quality?
- is the investment in quality (through quality management systems implementation) 
worthwhile?
1.4 Importance of the Study:
Pharmaceutical Industry in Palestine could be considered as a unique industry if 
compared  with  other  sectors  in  terms  of  its  innovation  and  development. 
Considering  the  importance  of  the  Pharmaceutical  sector  and  the  crucial 
performance  of  such  industry  within  the  Palestinian  economy  and  the  high 
demand for quality of pharmaceutical products, there is essential need for further 
in-depth  research  directed  at  studying  the  quality  management  systems 
implementation and the benefits  of these systems on opportunities  and needs 
imbedded within the sector's environment. The ultimate objective is to asses the 
impact  of  quality  management  systems  on  cost  and  competition  in 
pharmaceutical firms and to find the best way of getting benefits in promoting 
their  products  in  the  specialized  target  markets.  
  Quality is critical in the pharmaceutical industry for achieving both safety and 
efficacy.   Safety and efficacy of pharmaceutical  products are critical  and the 
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pharmaceutical industry is heavily regulated to assure the safety and efficacy, 
which  push  Pharmaceutical  companies  to  implement  effective  quality 
management  system  and  produce  according  to  international  manufacturing 
standards. Implementing effective quality management systems and producing 
according to international regulations (GMP) requires a lot of investment. On the 
other  hand,  by  assuring  safety  and  efficacy  of  the  products,  pharmaceutical 
companies  can  achieve  benefits,  like,  customer  satisfaction  and getting  more 
sales and better market share. The importance of this study is: 
-Lack of studies about impact of quality in Palestinian pharmaceutical industry 
on both customers and producers.
-  The study is a descriptive and it can be reference for further studies to search 
in depth in this sector.
- The outcome of the study can be used by the pharmaceutical industry to get 
better  benefits  of  implementing  quality  management  systems  and  complying 
with regulations and standards.
- The Ministry of Health can also, use the outcome of the study to improve this 
sector  and to  help Palestinian  pharmaceutical  industry competing  locally  and 
globally.
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1.5 Palestinian Pharmaceutical Industry as a focus of the 
research:
1.5.1 History
  Before the 1967 war, all pharmaceutical products were imported from foreign 
companies via importers in Amman, Jordan. After the 1967 war and isolating 
West Bank from the rest of Arab World, the only products available were either 
Israeli  medicine  products  or  products  imported  through  Israeli  agents,  and 
importing from Jordan was prevented. So, Pharmaceutical Industry in Palestine 
was developed to meet these challenges and offer the market some of the needs. 
In  1969,  nine  pharmacists  in  West  Bank  established  small  laboratories  to 
manufacture  simple  syrups  and anti-diarrhea  products.  In  1970 these  nine  small 
laboratories merged to become three larger companies:  Jordan Chemicals  in Beit 
Jala; Palestine Medical Company in Ramallah; and, Jerusalem Pharmaceuticals in 
El-Bireh. From 1972 – 1984, another seven companies were established:  Balsam 
Co. in El-Bireh in 1972 and Birzeit Co. in Birzeit in 1973; Eastern Medical Co. and 
Gama in 1978, both in Ramallah; and Pharmacare in 1985 in Beitunia, and MASCO 
in Gaza in 1984. During the 1990's, mergers occurred between some companies, like 
Birzeit  and Palestine  Medical  Company in  1993,  Jerusalem Pharmaceuticals  and 
Balsam in 1995, and Birzeit and Eastern Medical Co in 1997.  Currently, there are 
six major Palestinian companies predominantly located in the Ramallah area, where 
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70% of  local  producers  are  located,  all  of  which  are  members  of  the  Union  of 
Palestinian Pharmaceutical  Manufacturers (UPPM). Local production is relatively 
unfocused, with manufacturers tending to produce homogeneous product lines. This 
has  created  strong inter-industry competition  and has  weakened the sector  in  its 
attempt to develop and improve into a distinctive sector that invests in real research 
and development and benefits from economies of scale. Palestinian pharmaceutical 
companies are mainly, selling in the local market which is relatively small and this 
forces  companies  to  work  below  there  full  capacities.  According  to  Makhoul, 
(1999),  Palestinian  pharmaceutical  companies'  working  capacities  are  in  general 
below 83% of the full capacity,  and the limited market of these companies also, 
created sever competition,  and, in general,  companies produce identical  products. 
Moreover, companies severely compete in introducing high potential new products.
The Industry employed more than 857 persons, with total sales of about 32.2 Million 
USD  during  the  year  2003.  Recent  statistics  indicated  that  more  than  50%  of 
pharmaceuticals consumed in Palestine are Palestinian made. Although Palestinian 
manufacturers focus on generic products, they cover more than 80% of the needed 
product categories essential to combat diseases and relief sickness.
1.5.2  The  Development  of  Palestinian  Pharmaceutical 
Industry 
  The industry is growing rapidly targeting local as well as international markets. 
According  to  UPPM,  the  introduction  of  automated  production  lines,  improved 
management and production processes, continuous training of management and line 
workers  and  the  institution  of  quality  control  practices  have  led  to  significant 
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increases in production capacities. All six companies are currently participating in a 
program of  training  and  technical  assistance  aimed  at  complying  with  all  GMP 
requirements.  These  programs  have  been  reflected  in  the  continually  improving 
range  and  quality  of  products  and  increased  the  market  share  of  the  local 
manufacturers to nearly 40 percent of the estimated total market of $65 million with 
the balance being provided by Israeli and other international suppliers. Piece wise 
their  market  share  exceeds  50%.  Although  Palestinian  manufacturers  focus  on 
generic  products,  they  cover  more  than  80%  of  the  needed  product  categories 
essential  to  combat  diseases  and  relief  sickness.  There  are  12  major  product 
categories  (groups)  that  are  produced  by  the  Palestinian  manufacturers,  these 
categories are the best selling groups of products, constituting approximately 85-
90% of the total sales in the local market. Each category contains different generic 
products, ranging from 1 to 14 products per manufacturer and an average of three 
new products introduced annually by each producer. Under each product, there are 
different  brands,  forms,  dosage  and  sizes.  The  total  number  of  Palestinian 
pharmaceutical products is 991 items as registered by Palestinian Ministry of Health. 
Among the 12 categories, antibiotics capture the largest percentage of total sales, 
approximately  one-third  of  the  sales  of  all  products.  Central  nervous  system 
products and non-steroidal anti inflammatory come second with small differences 
between the two categories. The rest of the categories capture between 1 to 7 percent 
of the total sales, these categories are urinary antiseptic, anti diabetic, anti protozal, 
allergic reaction, hormones, anti fungal, vitamins, peptic ulcer, and cardio vascular.
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Table (2): Sales, Investment, Exports, and Employees of Palestinian Pharmaceutical 
Companies. 
1999 2000 2001 2002 2003
Sales ($) 20762532 22134037 20207730 23761755 32200000
Investment ($) 6670407 7304448 6388000 6411245 10666700
Exports ($) 855000 876470 764000 981781 1432000
Employees (No.) 600 631 656 732 857
  Source: UPPM, 2004
  Foreign products easily access the Palestinian market, while Palestinian products 
do  not  enjoy  access  to  Israeli  and  foreign  markets.  The  prices  of  Palestinian 
pharmaceuticals  are  relatively  controlled,  in  contrast  to  the  Israeli  and  foreign 
products. This may on one hand be an advantage, where local products can compete 
on prices against foreign products. However, it may be considered a constraint as far 
as profitability and development are concerned. Local manufacturers do not enjoy 
the same economies of scale as their  competitors;  in addition they do not obtain 
lower prices of their raw materials purchases because they do not buy in bulks. On 
the other hand, the cost of labor is less than that of Israel and foreign countries. This 
gives local manufacturers a labor cost advantage, although foreign companies use 
capital-intensive  operations.  This  advantage,  however,  might  be  offset  by  the 
inefficiencies and the capacity under-utilization of Palestinian factories. Moreover, 
Palestinian  pharmaceutical  industry  is  affected  by  Israeli  pharmaceutical 
competition  and  Israeli  products  can  easily  enter  Palestinian  market,  whereas, 
Palestinian products are not allowed to be soled in Israeli market.
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1.5.3 Palestinian pharmaceuticals toward complying with 
regulations and standards.
Several Palestinian companies are already investing millions of dollars in upgrading 
their facilities and equipment which required modernization of procedures to comply 
with the “Good Manufacturing Practices” (GMP) to face the following situations:
1- The  limited  market  in  Palestine  forces  manufacturers  to  seek  out  export 
market.
2- The increasing competition because of increased imports  of new products 
coming from neighboring Arab countries.
3-  Finally,  increasing  awareness  and  sophistication  among  Palestinian 
consumers, which require improved quality and higher standards.
  In  1986,  implementation  of  GMP  in  the  Palestinian  pharmaceutical  industry 
started, according to the guidance of the Institute for the Standardization and Control 
of Pharmaceuticals in Jerusalem. The Israeli requirements were the main ones. In 
1992, a guide to GMP requirements was prepared in Arabic, based mainly on the 
European Community guidelines, the Israeli Orange Guide, European GMP and the 
Israeli guide. Local manufacturers and concerned people, however, recommended 
the  use  of  the  guidelines  issued  by  the  Arab  Union  of  the  Manufacturers  of 
Pharmaceuticals and Medical Appliances (AUPAM), which had been adopted by the 
Arab  Ministers  of  Health  Council.  This  recommendation  was  made  because  the 
West Bank and Gaza Strip are part of the Arab world and future markets for the 
Palestinian  pharmaceutical  industry might  consist  of  Arab countries.  To date,  no 
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local company has been certified as GMP-compliant. However, some are believed to 
be  very  close.  It  is  expected  that  full  compliance  with  GMP  by  the  local 
pharmaceutical  industry will  increase the quality of drugs in the West Bank and 
Gaza Strip, for both the public and the private sectors.
   One major factor affecting the position of the Palestinian industries as a whole is 
the perception of the customers of the Palestinian products. For several reasons, this 
perception  was  very  negative,  for  the  pharmaceutical  industry  one  of  the  main 
reasons for this perception is the quality of information received by customers. Thus, 
during the last decade the Palestinian pharmaceutical companies struggled and still 
struggling to change this perception. A study conducted by the Ministry of Planning 
and International Cooperation in 1997 concluded that most of the pharmaceutical 
customer segments and intermediaries perceived the Palestinian pharmaceutical as 
of low quality and less effectiveness comparing to the Israeli and foreign products. 
In  2001  the  Union  of  Palestinian  Pharmaceutical  Manufacturers  UPPM  had 
commissioned a  consulting firm to assess  the status  of the industry's  image and 
consumer  attitudes  towards  industry  products,  targeting  a  number  of  key 
respondents:  physicians,  pharmacists,  health  services  providers  and  product  end 
users.  The  main  findings  of  this  study clearly  show a  significant  change of  the 
customer  perception  toward  the  Palestinian  drugs  and  the  image  was  generally 
positive with some variation of quality between the products of the same company 
or products from different companies. 
  In this study, four Palestinian Pharmaceutical Companies were selected, Birzeit 
Pharmaceutical  Company,  Jerusalem Pharmaceutical  Company,  Jordan Chemical 
Laboratory, and Pharmacare. The four companies lead the local market and have 
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the majority of the market share of local pharmaceutical companies (about 95% of 
local pharmaceuticals). These companies are working hardly to achieve high quality 
and to  produce according to  good manufacturing  practices.  The four companies 
have both ISO 9000- 2000 and ISO 14000 certifications and they are in advanced 
position in complying with cGMP, as international pharmaceutical manufacturing 
standards.
1.5.4 Ministry of Health Roles in Pharmaceutical Regulations
The pharmaceutical industry is highly regulated in most countries of the world if not 
in all countries. Specific international standards set by defined bodies should 
be followed by the manufacturers during the production process as well as for 
the final product itself. Batches’ testing is one of the main tools to insure high 
quality of products sold in the markets.  The Palestinian Ministry of Health 
(MOH) is the local official  body who is responsible for insuring quality of 
drugs in the market. The Center for Environmental and Occupational Health 
(CEOH) at Birzeit University recognized by MOH as the official Palestinian 
center  for  quality  control  for  pharmaceuticals.  The  MOH  and  the  CEOH 
classify the failure of pharmaceutical products into tow main categories, either 
minor or critical. If the test indicates a minor failure, the MOH send a warning 
to the company to solve the problem concerned within a specific period of 
time. If the failure is critical on the other hand, the product should be recalled 
and the product line is totally stopped. It has been never happened that there is 
any  critical  failure  recorded  during  quality  control  tests  that  done  by  the 
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CEOH. The pharmaceutical  products  sometimes  experienced  failure  during 
testing procedures, but this failure is common in the pharmaceutical testing 
process throughout the world. According to MOH statistics, in 1990’s 3% of 
the tested batches on average failed for minor  reasons as classified by the 
international standards and for non-critical reasons. During the last few years 
the average of failed tested batches has not been exceed 2%. The minor failure 
usually resulted if one or more of the following elements failed in the testing 
process: Assay, Color, Consistency, Labeling, Dissolution, PH-limit, Size and 
Registration.  
The  issue  of  quality  is  a  crucial;  all  products  manufactured  by  Palestinian 
companies  have  received  authorization  from  the  MOH  to  be  marketed.  For 
quality issues and testing procedures, it is possible for the new product to be in 
the market  within one year  of its  inception; however it  takes sometime three 
years for the Palestinian products to be approved by the MOH. This process is 
not applied on Israeli and foreign products, which gives them an advantage over 
the Palestinian drugs, and increase the cost for the local manufacturers.
The  following procedures  are  followed by the  MOH to register  and market  any 
pharmaceutical products:
1. The  applying  company  should  be  registered  as  a  pharmaceutical 
manufacturer.
2. The  applicant’s  product  line  must  meet  the  relevant  standards  and 
specifications.
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3. The  presented  application  should  contain  detailed  information  on  the 
product, bio-equivalency test, the mix, the use, side effects, etc.
4. Registration fees should be paid with the application.
5. The  MOH  issue  the  approval  within  six  months  from  the  application 
completion date.
6. The first three batches must be tested and analyzed before selling the product 
in the market.
1.6 Limitations of the study
-  The  study  is  conducted  on  four  Palestinian  pharmaceutical  companies. 
Therefore the results  of the study can't  be universally  generalized  due to the 
differences in perception, attitude and culture.
-  There  are  not  enough  studies  conducted  about  Palestinian  pharmaceutical 
industry.
- The difficulties of getting some statistics and accurate data.
- The study is a descriptive which could investigate the impact of quality from 
the perspective of top level managers and middle managers and supervisors of 
the companies.  And all  the data  were collected  from the companies.  So,  the 
results are in general, qualitative and to get more quantitative impacts, especially 
for costs, it is recommended for further in depth researches.
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1.7 Organization of the thesis
This research has been divided into six chapters. Chapter one is the introduction 
which includes a background about quality, cost and benefit of quality, and impact 
of  quality  on  competitiveness,  followed  by  purpose  of  the  study,  the  problem 
statement, a brief description of Palestinian pharmaceutical industry, importance of 
the study, and finally limitations. Chapter two provides a review of the literature in 
several  areas  and  characteristics  of  quality  and  its  impact  on  cost  and 
competitiveness in general and in pharmaceutical industry in specific, and finally a 
review  of  literature  about  Palestinian  pharmaceutical  industry.  Chapter  three 
describes  the  quality  control  and  assurance  in  pharmaceutical  industries  and 
description of standards and regulations that pharmaceutical manufacturers should 
implement to survive and globally compete. Chapter four  explains the methodology 
used in collecting data including the design of the research, limitations of the design 
and scale,  how the  sample  has  been  selected,  and reliability  and validity  check. 
Chapter five provides description of the data collected from the questionnaires and 
the interviews of the opinion leaders and the corresponding analysis.  Chapter six 
presents  the  discussion,  conclusions,  and  recommendations  to  Palestinian 
pharmaceutical  industry  as  the  focus  of  the  research,  the  contribution  to  the 
theoretical and practical knowledge, and finally recommendations to other studies.
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1.8 Definition of terms
Appraisal  Cost:  any  cost  incurred  in  an  effort  to  detect  a  failure  in  meeting 
requirements, (Oakland (1993).
Cost of Quality (COQ):   the total of the costs incurred through (a) investing in the 
prevention of non-conformance to requirements; (b) appraising a product or service 
for  conformance  to  requirements;  and  (c)  failure  to  meet requirements  (the 
American  Society  for  Quality  Control  (ASQC))  
External Failure Cost: any cost incurred for products that do not meet requirements 
and have been transferred to the customer, (Oakland, 1993).
Good Clinical Practice (GCP): A standard for the design, conduct, performance, 
monitoring,  auditing,  recording,  analyses,  and  reporting  of  clinical  trials  that 
provides assurance that the data and reported results are credible and accurate, and 
that  the rights,  integrity,  and confidentiality of trial  subjects  are protected,  (ICH, 
1996).
Good Laboratory Practices:  a quality system concerned with the organizational 
process  and  the  conditions,  under  which  non-clinical  health  and  environmental 
safety studies are planned, performed, monitored, recorded, archived and reported, 
(www.oecd.org/department, 2004).
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Good Manufacturing Practices (GMP): are considered part of the Quality Control 
System for companies producing food or pharmaceutical products. GMP principle 
aims  to  ensure  the  regular  production  for  products  that  confirm with  the  health 
standards  required  from regulatory  Bodies.  GMP provides  the  general  basics  to 
determine  the  minimum  acceptable  requirements  for  the  production  at  Good 
products,  covering  all  the  activities  related  to  the  production  process, 
(http://www.fda.gov/cder/gmp/gmp2004/GMP_finalreport, 2004). 
Internal Failure Cost: any cost incurred for products that do not meet requirements 
and have not been transferred to the customer, (Oakland, 1993).
ISO  14000:   series  of  voluntary  environmental  standards  developed  by  the 
International  Organization  for  Standardization  (ISO),  a  worldwide  group  that 
promotes uniform standards. ISO 14000 is a voluntary standard designed to provide 
a  consistent  means  of  managing  environmental  impacts  of  business  operations, 
(www.iso.org).
ISO 9000 series: A set of international standards on quality management and quality 
assurance  developed  to  help  companies  effectively  document  the  quality  system 
elements to be implemented to maintain an efficient quality system, which were first 
published in 1987, (www.iso.org). 
Prevention Cost: is any cost incurred in an effort to prevent a failure in meeting 
requirements, (Oakland, 1993).
Quality Assurance (QA):  All the planned and systematic activities implemented 
within the quality system and demonstrated as needed, to provide adequate 
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confidence that an entity (service, product, process, activity, organization) will fulfill 
the requirements for quality, 
(http://www.fda.gov/cder/gmp/gmp2004/GMP_finalreport, 2004). 
Quality Control (QC): The operational techniques and activities that are used to fulfill 
the requirements for quality, 
(http://www.fda.gov/cder/gmp/gmp2004/GMP_finalreport, 2004). 
Quality  Management System: a  structured  and documented  system describing  the 
policies,  objectives,  principles,  organizational  authority,  responsibilities, 
accountability, and implementation plan of an organization for ensuring the quality 
in its work processes, products, items, and services. The quality system provides the 
framework  for  planning,  implementing,  and  assessing  work  performed  by  the 
organization and for carrying out required QA and QC, (ANSI/ASQ, 1995).
Requirement: A formal statement of a need and the expected manner in which it is 
to be met, (EPA, 2002). 
Standards: A document, established by consensus and approved by a recognized 
body  that  provides,  for  common  and  repeated  use,  rules,  guidelines,  or 
characteristics  for  activities  or  their  results,  aimed  at  the  achievement  of  the 
optimum  degree  of  order  in  a  given  context." (International  Organization  for 
Standardization (ISO). http://www.iso.ch/infoe/ (2/18/99))
Standard Operating Procedures  (SOPs):   A written  document  that  details  the 
method for an operation, analysis, or action with thoroughly prescribed techniques 
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and steps and that is officially approved as the method for performing routine or 
repetitive tasks (EPA, 2002).
Total Quality Management (TQM): The integration of all functions and processes 
within an organization in order to achieve continuous improvement of the quality of 
goods and services. 
Validation: Establishing  documented  evidence which provides a high degree of 
assurance that a specific  process will consistently produce a product meeting its 
pre-determined  specifications  and  quality  attributes. Process  validation  is  a 
requirement of the Current Good Manufacturing Practices Regulations for Finished 
Pharmaceuticals and of the Good Manufacturing Practice Regulations for Medical 
Devices,  and therefore,  is  applicable  to  the manufacture  of pharmaceuticals  and 
medical devices (EPA, 2002).
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CHAPTER TWO
Literature Review
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Literature Review
This chapter is divided into four parts as follows:
• Part one reviews the concept and definition of quality and the role of 
quality management systems on pharmaceutical industry.
• Part two reviews the cost of quality
• Part three reviews the quality and the competitive strategy.
• Part  four  reviews  the  studies  that  have  been  conducted  about 
Palestinian pharmaceutical sector.
2.1 The role of quality management in pharmaceutical 
industry
Every pharmaceutical  product has established identity,  strength, purity,  and other 
quality  characteristics  designed  to  ensure  the  required  levels  of  safety  and 
effectiveness.  So,  achieving  quality means achieving these characteristics  for the 
product. The following characteristics of a drug determine its quality:
· Identity: The correct active ingredient is present.
· Purity: The drug is not contaminated with potentially harmful substances.
33
· Potency: The correct amount of active ingredient is present, usually between 95 
and 110 percent of the labeled amount.
· Uniformity: Consistency, color, shape, and size of the dosage form do not vary.
· Bioavailability: Bioavailability refers to the speed and completeness with which an 
administered drug enters  the blood stream.  This  must  be consistent to provide a 
predictable  therapeutic  result.  Drug  bioavailability  differences  exist  between 
manufactures of the same product. Therefore, careful evaluation of generic drugs 
may be necessary before purchase and use.
· Stability: The activity of the drug is ensured for the period of time stated on the 
product label, that is, until the expiration date.
· Pharmacopoeia standard: A drug is of good quality if its characteristics meet the 
standards  described  in  a  widely  accepted  pharmacopoeia  such  as  the  British 
Pharmacopoeia (BP), European Pharmacopoeia, International Pharmacopoeia (IP), 
or United States Pharmacopoeia (USP).
  Quality  management  in  the  drug  industry is  discussed  in  the  WHO GMP for 
Pharmaceutical Products. In this document the following are presented:
• The basic elements of quality management are:
- An appropriate infrastructure or “quality system”, encompassing the organizational 
structure, procedures, processes, and resources; and
-  Systematic  actions  necessary to  ensure  adequate  confidence  that  a  product  (or 
service) will satisfy given requirements for quality. The totality of these actions is 
termed “quality assurance”.
•  The  concepts  of  quality  assurance,  GMP,  and  quality  control  are  interrelated 
aspects  of  quality  management.  They  are  of  “fundamental  importance  to  the 
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production  and control  of  pharmaceutical  products”.  QA encompasses  all  of  the 
arrangements made to ensure that pharmaceutical products meet the quality required 
for their intended use. Although QA is not specified in all
GMP documents, the WHO GMP guidelines (ref 27) present the principles of QA 
are  to  ensure  that  GMP  and  other  regulatory  codes  (GLP  -  Good  Laboratory 
Practice, and GCP - Good Clinical Practice) are respected; that responsibilities are 
clearly specified; all testing, controls, calibrations, validations, etc are performed as 
specified;  that  products  are  not  sold before the correct  authorizations  have been 
obtained; that products are appropriately handled throughout their shelf-life; and that 
there is a procedure for self inspections (quality audit).
Quality  is  not  a  new  or  recent  development,  but  now,  quality  has  become  an 
increasingly predominant feature of our lives and people are constantly involved in 
the search for quality products, quality services and even quality time with which to 
share with their partners and families (Walsh, Hughes and Maddox, 2002). 
    The quality means a lot in pharmaceutical industry and this sector has its own 
characteristics.  Alongside  other  industries  where  safety  is  critical,  the 
pharmaceutical industry is heavily regulated and for obvious reasons: mistakes in 
product design or production can have severe, even fatal, consequences for patients 
(Gough, 1999; McAdam and Barron, 2002).  
The  pharmaceutical  industry  in  the  world  represents  a  considerable  economic 
weight: the market is estimated at US$300,000 million, with a demand continuing to 
grow year after year (due in particular to the aging of population, evolution of life 
styles,  appearance  of  new  pathologies,  prevention  policies,  etc).(  Hermel  and 
Bartoli, 2001).
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     EC directives  91/356/EEC and  91/412/EEC state:   The  manufacturer  shall 
establish  and  implement  an  effective  pharmaceutical  QA  (Quality  Assurance) 
system, involving the active participation of the management and personnel of the 
services involved. To ensure quality and safe products, pharmaceutical companies 
build their quality approach around good manufacturing practice (GMP). Validation 
and  auditing  are  widely  used  to  assess  the  effectiveness  of  pharmaceutical 
companies’  quality  control  (QC)  and  quality  assurance  (QA)  systems.  Good 
Manufacturing Practice (GMP) is part of QA aimed at ensuring that products are 
consistently  manufactured  to  the  required  quality.  "QC  is  part  of  GMP  and 
comprises: the testes, inspections and measurements  carried out on samples taken 
before,  during  and  after  manufacturing  and  packaging  to  provide  events  that  a 
finished  product  will  or  will  not  meet  its  written  specifications"  (  Rowley  and 
Sneyd, 1996).
  Bashe (2000), stated that the increase in consumer power will fundamentally force 
pharmaceutical companies to change the way they do business, which makes quality 
now a major differentiator in this increasingly competitive business environment.
According  to  Grobler,  (1995),  the  increasing  competitiveness,  indicates  that 
managers have to maintain effective control of their companies through effective 
management skills and systems. These management skills help managers to be able 
to measure the day to day performance. Without measurement, effective control is 
impossible.
2.2 Cost and benefit of Quality 
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  Developing and maintaining quality systems can be viewed as efforts that  cost 
money or efforts that  save money.  Products and/or services that meet customers’ 
needs,  produce  customer  satisfaction,  and  are  free  of  defects  generate  revenue 
(Kastango,  2002).  As cited  by Motwani,  (2001),  Deming mentioned that,  higher 
quality  leads  to  less  rework,  lower  costs,  higher  productivity,  lower  prices,  and 
increased market share, as quality measures that affect business performance.
  As mentioned by Suarez, (1991), Crosby (1984) stated that, quality is either present 
or not present. There is no such thing as differing levels of quality.  Management 
must  measure  quality  by  continually  tracking  the  cost  of  doing  things  wrong. 
Crosby, (1984) referred to this as the price of nonconformance. To aid managers in 
tracking the cost of doing things wrong, he developed the following formula:  Cost 
of  Quality  (COQ)  =  Price  of  Conformance  (POC)  +  Price  of  Nonconformance 
(PONC).  The POC refers to the cost  of getting things done right the first time. 
PONC  provides  management  with  information  regarding  the  wasted  cost  and  a 
visible indication of progress as the organization improves.
 According  to  Chen  and  Yang,  (2002),  Cost  of  quality  (COQ)  concepts  affect 
operating costs, profitability, and customer needs.  COQ is a significant cost driver 
that firms need to control effectively to sustain their competitive advantage. 
     These absolutes help management  focus on quality improvement  and,  more 
importantly, help them make the shift from what Crosby calls conventional wisdom 
(the idea that if quality goes up, so does the cost) to the idea that quality and costs 
are not in competition with each other.  According to Crosby, (1979), as quality 
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increases, cost decreases--thus, quality doesn't cost. This reasoning led to Crosby s 
famous phrase, Quality is free, but it is not a gift. 
  However, tracking cost of quality stills limited and is not widely used. Sower and 
Quarles,  mentioned  that  there  is  a  need  to  track  cost  of  quality  to  translate the 
language of things that quality professionals use (e.g. defects, units) to the language 
of dollars that managers use (e.g. costs, financial performance).  As Cited by Sower 
and Quarles, Evans and Lindsay, (2002) mentioned that the use of dollars instead of 
defect  rates  also  makes  it  easier  to  aggregate  performance  measures  across 
departments or divisions and to compare to other dollar measures. 
  For many years, the concept of economics of quality was known as a cost reduction 
tool and has applied to the three levels of quality costs Prevention, Appraisal, and 
Failure costs (PAF Model) which has been developed by Feingenbaum, (1961), and 
Process Cost Model. But effects of the both two models are very limited, because 
they look only at  the  production  costs  and the larger  portions  of  total  costs  are 
hidden under the title of overheads.  According to Carr, (1995), by implementing a 
program called  Cost  of  Quality  (COQ) in  1989;  Xerox saved the  company $53 
million,  $77 million in  1990 and $20 million  in  1991.  However,  Xerox was  no 
longer able to use COQ effectively. Therefore, any company can follow in Xerox’s 
success of the implementation of COQ but must be aware of how eventually the 
COQ system broke down at Xerox.  
Omachonu;  Suthummanon,  and  Einspruch,  (2003),  concluded  that  there  is  an 
inverse relationship  between appraisal  cost  plus prevention  cost  and failure  cost, 
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there is a direct relationship between appraisal cost plus prevention cost and quality, 
and there is an inverse relationship between failure cost and quality.
The quality cost data can be used in an effort to be proactive, and to identify causes 
of  problems.  It  provides  a  methodology  for  pinpointing  improvement  priorities. 
Once the causes are resolved, the defects do not occur and failure costs decrease, 
(Omachonu; Suthummanon, and Einspruch, 2003). 
In  pharmaceutical  industry,  quality  assurance  has  economic  impacts  on  both 
medicine producers and consumers. For the producer, Applying quality assurance 
from the very start of production has important economic benefits, which means that 
detecting and correcting or rejecting any defect or process faulty at the very start of 
the procedure is more economical than detecting it after finishing the production or 
at late stages of production which leads to discard the whole batch of fully processed 
finished product. Quality costs money, but the cost of not applying quality assurance 
in the pharmaceutical manufacturing is much higher (IFPMA, 1997). 
  McDonald, (2003), determined seven elements for life science firms to reduce the 
risks  and  high  costs  associated  with  not  complying  with  current  Good 
Manufacturing Practices (cGMP) into an effective training strategy.   An effective 
training  strategy includes  Teaching  the  theory behind  the  practice,  Allowing for 
experience  sharing  during  training,  Motivating  learners  to  learn,  Allocating  the 
appropriate amount of training time, Creating a comfortable learning environment, 
Choosing an effective trainer, and Evaluating the learning experience. 
  According to Kastango, (2002), developing and maintaining quality systems can be 
viewed as efforts that cost money or efforts that save money. But because products 
or services will generate revenue, if they meet customers' needs, produce customer 
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satisfaction, and they are free of defects, so, quality systems can be considered as 
efforts that save money for organizations that adopt it. 
  Walsh, Hughes, and Maddox, (2002), mentioned that a TQM philosophy offers 
many 
• The elimination of defects;
• Reduced scrap and rework;
• Reduced levels of cost;
• Increased levels of efficiency and productivity;
• Increased employee morale and motivation.
 Implementing TQM in ICI pharmaceuticals in Australia helped the company to 
save  $2million  in  its  working  capital  in  one  year  (1991-  1992), 
(www.oliverwight.com/client/successes/ici.). The savings were resulted from: 
• Stock Reduction, about 38% as a percent of sales.
• Slash cycle time reduction by 50%.
• Sales increase by 15%
• More and frequent communications between sales and marketing group 
and operation group which helped the company to manage the production 
and sales in shorter lead time.
 There are many benefits of TQM implementation in pharmaceutical companies and 
some of the most important of these are less reworks, cost reduction, and improving 
productivity and efficiency (Rowley and Sneyd, 1996; McAdam and Barron, 2002). 
Rowley  and  Sneyd,  (1996),  found  that  the  cost  of  implementing  TQM  in  a 
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pharmaceutical ranged from £ 1- £ 500k, the estimated savings are ranged from £ 1k 
- £ 1m.
According to Asubonteng, McCleary and Munchus, (1996), TQM is implemented in 
health care to improve quality and reduce costs, through many strategies including, 
identifying and meeting customer needs, reducing the cost of non-compliance with 
standards,  striving for zero defects,  reducing outcome variability,  eliminating the 
cost of poor quality, using statistical methods to identify and monitor processes, and 
continually working for improved quality.
Cost of quality must be kept at an acceptable level. If the cost is too high it may 
have significant implication with regard to competitive pricing (Mehra and Agrawal, 
2003). 
  Rust, Moorman, and Dickson, (2002), mentioned that financial results from quality 
improvements can come from increased revenues, decreased costs, or both at once. 
Companies  can  increase  revenues  by  making  their  goods  and  services  more 
appealing, which increases customer satisfaction. Likewise, they can decrease costs 
by  making  their  operations  more  efficient.  After  testing  the  strategies  across  a 
sample of 71 business units, Rust, Moorman,   Dickson, (2002), found that emphasis 
on increasing revenues may be better  than an emphasis  on decreasing costs or a 
simultaneous emphasis on both revenues and costs and companies in the sample that 
emphasized  quality  improvements  focused  on  revenue  expansion  had  better 
financial performance—both self-reported by managers and measured objectively by 
return on assets and stock returns. These results suggest that revenue-building efforts 
such as efforts to improve customer satisfaction and customer loyalty may be more 
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profitable  than  cost-reducing  efforts.  The  results  also  suggest  that  it  should  be 
difficult  for  firms  to  build  customer  satisfaction  and  customer-perceived  quality 
profitably in an environment that is steeped in cost-reduction methods. The results 
suggest that having a market orientation within the firm is not enough; there should 
also be a stronger emphasis on the customer than on internal efficiency because of 
the inevitable trade-offs between the two. 
As  mentioned  by  Destefani,  (2004),  The  FDA  estimates  that  total  annual 
incremental  costs of the new CGMP regulations  to U.S.  device manufacturers  at 
about  $81.9  million.  But  these  costs  are  more  than  offset,  the  agency  says,  by 
benefits to public health and by economic benefits to the medical device industry.
FDA' s best estimates indicate benefits to public health will include 36 to 44 fewer 
deaths, and 484 to 677 fewer serious injuries per year that are attributable to design-
related device failures.
What's  a  human  life  worth?  According  to  the  FDA,  studies  on  the  value  of  a 
statistical-life  have reported estimates  ranging from $1.6 million to $8.5 million. 
Assuming an economic value of $5 million per fatality avoided, the monetary value 
of saving 36 to 44 lives each year will be $180 to $220 million. Therefore, the value 
of the public health benefits of preventing deaths alone easily exceeds the cost of 
compliance  even  without  estimating  benefits  from a  reduced  number  of  serious 
injuries, the agency says.
Economic benefits  to medical  device manufacturers will  result from cost savings 
due  to  fewer  design-related  product  recalls,  better  product  quality,  and  greater 
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productivity.  The  agency received  reports  on  an  average  of  359 medical  device 
recall events per year between the years1988 to 1991. Based on data from a recent 
survey of recall  costs, FDA estimates that the industry would avoid roughly $29 
million  worth  of  recall  expenses  per  year  by  complying  with  the  final  CGMP 
regulation.
Finally,  because the EU is  adopting ISO 9000 as a  basis  for  its  medical  device 
manufacturing quality system, harmonization of the two quality requirements will 
eliminate the need for device manufacturers to maintain different quality systems for 
each market. Reciprocity for quality assurance inspections could save the medical 
device industry millions of dollars.
  Maani, Putterill and Sluti, (1994), concluded that their study has been able to show 
empirically that in manufacturing companies, improving quality positively enhances 
operational  performance  and  productivity,  and  certain  indicators  of  business 
performance.  The  association  is  most  pronounced  between  quality  and  process 
utilization, with the second largest impact of quality being on manufacturing costs. 
However, the majority of firms are improving quality for competition and image 
improvement  more  than focusing on impact  of  quality on productivity  and cost. 
These findings were supported by a subsequent survey of manufacturing trends in 
New Zealand which conducted by, Corbett, (1990) in which managers rated quality 
as the element most needed to compete successfully in the marketplace.
Quality  costs  are  powerful  indicators  to  motivate  management  to  go  to  TQM 
programs. By reporting grand total costs of quality, management can be convinced 
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of the need to improve quality.  Reporting quality costs as a percentage of profit, 
quality costs as a percentage cost of goods sold, quality costs as a percentage of 
product prices, and so on; management can be presented with the size of a quality 
problem. This will also stimulate management to look for opportunities to reduce 
costs.  The  opportunity  costs  of  lost  sales  will  force  management  to  think  about 
reducing customer dissatisfaction and defection to competitors. The COQ concept 
will also help a company introduce a financial control system for the quality control 
function (Madu 1998). 
  Firms should strategically plan for quality improvement and they must allocate 
required  resources  for  successful  quality  management  systems  implementations. 
This will enable the firms to get benefits from the link between quality management 
and business performance. As mentioned by Chapman, Murray and Mellor (1996); 
Garvin,  (1988)  found  a  strong  correlation  between  productivity  (both  labor  and 
capital) and quality as well as between profitability (ROI) and quality. Garvin found 
that the relationships between quality and profitability were less well  established 
because  of  the  many other  variables  affecting  ROI  measures.  Moreover,  Maani, 
Putterill,  and  Sluti,  (1994),  found  strong  relationships  between  productivity 
improvement and organizational success in customer satisfaction programs, product 
quality improvement, reduction in waste and strategic quality improvement. 
2.3 Quality and Competitive strategy
  For organizations, the focus of quality lies in how to continually achieve customer 
satisfaction. Juran and Gryna (1980) defined quality as ``fitness for use’’. Similarly, 
Crosby (1979) identified quality as meaning ``conformance to requirements’’. Both 
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of  these  definitions  focus  on  the  satisfaction  of  customer  needs.  The  key  to 
competitive advantage lies in continuously satisfying your  customers’  needs in a 
fashion that is superior and more consistent than your competitors. Organizations 
should be aware about customer needs and wants, and anticipate the future needs 
and wants of the customer (Linus Osuagwu, 2002). The emphasis on customer or 
client  requirements  should  be  determined  from the  customer  requirements  for  a 
product/service  including  specification,  performance,  reliability,  value  for  money 
and  on-time  delivery  at  the  lowest  cost  (Bank,  1992).  Deming  (1986)  has  seen 
competition as a function of customer/client satisfaction. 
   As mentioned by Kastango, (2002), Juran, 1994 classified the effect of quality in 
Compounded Preparations into two approaches:   effects of high-quality products 
that meet customers’ needs and effects of high-quality products that are free from 
defects. Meeting customers'  needs leads to increase customer satisfaction, sell for 
premium prices, meet or exceed the quality of competitive products, increase the 
market  share  of  the  product  sold,  provide  sales  income.  Producing  high  quality 
products that are free of defects has benefits in reducing error rates, reducing the 
need  to  rework  the  preparation,  reducing  the  number  of  field  failures,  warranty 
claims,  and  waste,  reducing  customer  dissatisfaction,  reducing  the  number  of 
inspections required and the need for product testing, increasing product yield or 
output,  enabling  greater  operating  capacity  and efficiency,  and  improve  delivery 
performance. 
  There  are  different  scenarios  of  quality  movement  of  tomorrow.  There  is 
continuous changing of market dynamics, new challenges that change new global 
markets constantly causing stressful competitive environments. Businesses operating 
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beyond their national boundaries cannot depend upon previously proven domestic 
quality practices. Therefore, a global business may have to revise its quality-based 
elements of competitive strategy,   (Mehra and Agrawal, 2003).  
   The emergence of quality as a top priority in many corporate entities is primarily 
due to the globalization and competitive pressure brought about by the escalating 
demands  of  consumers,  who want  better  products  and  services.  Globalization  of 
markets and the fast improvements in information flow capabilities have increased 
competition  worldwide.  In  order  to  compete  in  today’s  turbulent  competitive 
business environment, organizations are focusing on the satisfaction of customers’ 
needs as a means of securing competitive advantage and even survival (Magd and 
Curry 2003). According to Kranton, (2001), the increased of global competition and 
improved communications have lead to greater customer expectation. Because price 
competition can eliminate  the profits  necessary to induce firms to produce high-
quality goods, industry associations may play a role in guaranteeing product quality. 
So, competition motivates firms to provide the highest quality at the lowest price to 
meet customers' expectations and satisfy there needs (Henderson Committee, 1992; 
Watson, 2002,).  Latham Report, (1994), concluded that "Total quality management 
is a way of managing an organization to ensure the satisfaction at every stage of the 
needs and expectation of both internal and external customers, that is shareholders, 
consumers  of its  goods and services,  employees  and the  community in which it 
operates, by means of every job, every process being carried out right, first time and 
every time’".  Continuous improvement  is  a  basic  tenet  in  TQM that  can  enable 
manufacturers to meet the competitive pressures of the global economy head-on, and 
to  develop  strategies  for  making  products  that  are  both  high  in  quality  and 
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commercially  successful.  For  device  manufacturers  faced  with  a  competitive 
marketplace  made  up  of  increasingly  demanding  customers,  continuous 
improvement can be more than merely a formal system of business management. 
Companies that do not continuously improve everything they do for their customers 
may soon find themselves out of business (Sahni and Gaertner1996).
   Many corporate enterprises have found that the key to competitive success lies in 
emphasizing product and service quality as a strategic issue when doing business 
(Kano, 1993; Belohav, 1993; Pulat,  1994). According to Tan, Kannan, Handfield 
and Ghosh, (2000) if companies strive to compete in increasingly competitive global 
markets,  it  is natural  to view quality as one way by which they can do so. It is 
apparent however that a lack of clarity exists regarding the strategic use of quality 
and responses  to  global  competition.  Survey results  indicate  that  innovation  and 
effective  product  development  are  crucial  to  providing  a  response  to  global 
competition.  However,  while  companies  strive  to  improve  the  quality  of  their 
products, they cannot overlook the threat from companies that have been able to 
reduce costs while maintaining high quality standards. But, even in the absence of 
competition,  improvements  in  quality  can  facilitate  an  organization's 
competitiveness, though as witnessed over the last decade, competition has for many 
organizations been the driver of quality improvement efforts.  
  Over the last few years the global pharmaceutical market has undergone significant 
change,  forcing  pharmaceutical  companies,  more  than  ever  before,  to  focus  on 
customer  needs  and  upon  their  own  internal  efficiency  in  order  to  continue  to 
compete effectively.
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   Unmet medical needs, an aging population, rising health-care costs, and sparse 
pharmaceutical  pipelines  are  forcing  healthcare  companies  to  reevaluate  their 
competitive  strategies.  Also,  consumers  are  playing  a  larger  role  in  healthcare. 
Patients are more knowledgeable and assertive regarding their individual healthcare 
decisions and are putting additional pressure on the industry to lower cost through 
innovation (Mendricks, Vanroeyen, And Wang, 2003). 
  To  improve  competitiveness,  organizations  are  looking  for  a  higher  level  of 
effectiveness  across  all  functions  and processes  and are  choosing (TQM) as  the 
application  of  quality  principles  and  common  factors  for  the  integration  of  all 
functions  and  processes  within  the  organization  in  order  to  stay  in  business 
(Oakland, 2000).  
Buttle, (1996) concluded that companies pursue ISO 9000 certification in order to 
enjoy both operational and marketing benefits which impact on costs, revenues, and, 
by inference, profit.
The most important benefit sought from certification is profit improvement, second 
are  process  improvements  and  third  most  important  are  marketing  benefits. 
Marketing  benefits  include  gaining  new  customers,  keeping  existing  customers, 
using the standard as a promotional tool, increasing market share, increasing growth 
in sales and improving customer satisfaction. 
2.4 Studies about Palestinian   Pharmaceutical Industry: 
  The  global  pharmaceutical  competition  is  based  on  the  quality,  products 
effectiveness,  and  innovation  more  than  price  competition.  But  in  Palestinian 
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market,  because  of  the  similarities  of  the  local  products,  it  is  mainly  price 
competition (Makhool, 1999). 
  By conducting a study to identify ways to improve product sales performance and 
to increase market share of Palestinian pharmaceutical companies in a competitive 
and  rapidly  changing  environment  through  increased  consumer  awareness  and 
enhanced positive perception, Massar,2000, found that to define  technical quality it 
is necessary to list certain features that are considered as quality of the product and 
each segment of the customers can define the product quality according to certain 
features  that  satisfy  there  own  needs.  For  consumers  (end  users),  product  is 
ambiguous, and patient satisfaction is one measure used to assess the performance of 
pharmaceuticals.  Doctors  and pharmacists  define quality as product  effectiveness 
and safety, whereas Ministry of Health determined two dimensions to define quality: 
first, quality is to comply with good manufacturing practices (GMP) and second, is 
the safety. 
   According  to  Makhool,  (1999);  Massar,  (2000);  Obeidallah,  et  al,  (2000), 
Palestinian pharmaceutical products quality is good. All the Palestinian companies 
have recognized the importance of commitment to Good Manufacturing Practices, 
and four of them are seriously seeking the GMP certificate,  but tell  now no one 
could  achieve  it,  which  affects  the  competitiveness  of  these  companies  in  the 
external market.   
     There  are  differences  of  quality  of  pharmaceutical  products  between  the 
Palestinian  companies  and  between  different  products  of  the  same  company 
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(Makhool,  1999; Massar,  2000).   However,  there  is  a major  problem still  facing 
Palestinian pharmaceutical industries which is the customer perception. According 
to  Massar,  (1997),  8%  of  customers  (Doctors  and  pharmacists)  believe  that 
Palestinian pharmaceutical products are not up to standard. According t o Massar, 
2000,  the  general  evaluation  of  Palestinian  pharmaceuticals  is  positive.  67% of 
doctors and 65% of pharmacists believe that Palestinian Pharmaceuticals are having 
good quality  and some of  these  products  can  equally  compete  with  foreign  and 
Israeli products, but there is significant percentages of doctors (32%), pharmacists 
(34%) and households (41%) believe that Palestinian pharmaceutical products are 
moderate. There are significant proportions of doctors and pharmacists still perceive 
Palestinian  pharmaceutical  products  as  non-  competitive  to  foreign  products 
(Massar, 2000).      
50
CHAPTER THREE
Pharmaceutical regulations and 
standards
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3.1 Introduction 
  In pharmaceutical market, there are two types of regulations and standards, the 
regulation of the organization and the government interference (health authorities), 
because it differs from other markets in several important characteristics which do 
not apply to other consumer goods. Broun, (1994), summarized these characteristics 
as follows: 
(a)  The  user  (patient)  generally  does  not  select  the  drug--  it  is  prescribed  by  a 
physician or other health worker; 
(b) In the case of over-the-counter medicine, the patient may select the drug, but he 
or she lacks the specialized knowledge to make a critical  comparison of various 
products in terms of suitability, quality, and value for money. 
(c) The health workers build their knowledge about the drug, mainly, from the seller, 
and they are insufficiently trained to make a full assessment of drugs. Furthermore, 
positive  results  of  pre-  marketing  studies  of  safety  and  efficacy  are  sometimes 
contradicted by results when the drugs are used widely. 
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(d)  The  user  is  often  insulated  from  the  price  consequences  of  consumption 
decisions, as the public sector or private insurers often pay for the drugs; 
(e) Even after the drug has been taken, neither the user nor the health care provider 
is fully able to assess its effects, since these are highly variable and the course of the 
ailment may be influenced by other factors. 
(f) In cases where the user might in theory be capable of objective assessment, this 
can be impaired by hope and expectations: some 35 percent of the physically ill and 
40 percent or more of the mentally ill respond to an ineffective product (placebo).
(g) Fear of illness can create illogical and costly demands: health professionals and 
patients have often generated a vast demand for worthless drugs. 
  So, the need for high standards built by governments and health authorities,  to 
ensure that  drugs are effective,  pure and of consistent quality,  has grown further 
with  the  increasing  sophistication  of  drugs  in  the  20th  century,  as  many 
contemporary products can only be adequately produced under highly specialized 
industrial  conditions.  Detailed  standards  of  "Good  Manufacturing  Practice"  for 
pharmaceuticals  have  been  laid  down  in  recent  years  and  have  been  widely 
recognized  and  implemented.  WHO defined  global  standards  in  1987  but  some 
national authorities require substantially higher standards, such as US-FDA.  Quality 
control  systems  and  regulations  are  built  to  assure  that  pharmaceuticals  of  low 
quality,  either  imported  or  locally  produced,  should  not  reach  the  population. 
However, upgrading of manufacturing standards often has to be staged over time. 
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Regulations  regarding  quality  must  be enforced by a  well-organized  and trained 
inspection administration and independent from commercial pressure.  
  Internally,  the  manufacturer  should  establish,  document,  and  implement  an 
effective  system  for  managing  quality  that  involves  the  active  participation  of 
management and appropriate manufacturing personnel.
 The system for managing quality should encompass the organizational structure, 
procedures, processes and resources. All quality related activities should be defined 
and documented.
 There should be a quality unit(s) that is independent of production and that fulfills 
both quality assurance (QA) and quality control (QC) responsibilities. 
   Quality assurance is  a system of activities  designed to ensure production that 
meets pre-established requirements. It gives the customer a guarantee of quality by 
measuring  product  conformance  with  processes  and  performance  specifications. 
Quality  improvement  refers  to  all  efforts  directed  to  increase  effectiveness  and 
efficiency in meeting accepted customer expectations. It is a continuous process to 
achieve a better understanding of the market; to innovate products and processes; to 
manage and distribute material and products; and to provide service to customers. 
The success of quality improvement is based on an understanding by every member 
of the organization concerning the needs of their customers (internal and external) 
(Schlenker, 1998).
   All quality related activities should be recorded at the time they are performed and 
any deviation  from established  procedures  should be documented  and explained. 
Critical deviations should be investigated, and the investigation and its conclusions 
should be documented.
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 No  materials  should  be  released  or  used  before  the  satisfactory  completion  of 
evaluation by the quality unit(s)  unless there are appropriate  systems in place to 
allow for such use.
 Procedures should exist for notifying responsible management in a timely manner 
of  regulatory  inspections,  serious  GMP deficiencies,  product  defects  and  related 
actions (e.g. quality related complaints, recalls, regulatory actions, etc.).
    The knowledge of WHO, EU, and US- FDA GMPs is becoming a necessary 
aspect of doing business in today's market.  Medicinal products have to fit for their 
intended  use,  comply  with  the  requirements  of  the  national  and  international 
standards and regulations and do not place patients at risk due to inadequate safety, 
quality or efficacy. The attainment of this quality objective is the responsibility of 
senior management and requires the participation and commitment by staff in many 
different  departments  and  at  all  levels  within  the  company,  by  the  company’s 
suppliers  and by the distributors.  To achieve  the quality objective reliably there 
must be a comprehensively designed and correctly implemented system of Quality 
Assurance  incorporating  with  Good Manufacturing  Practice  and  thus  Quality 
Control. All parts of the Quality Assurance system should be adequately resourced 
with  competent  personnel,  and  suitable  and  sufficient  premises,  equipment  and 
facilities.  
In general, the pharmaceutical industry is accustomed to working with regulatory 
standards (Rowley, and Sneyd 1996), which include:
• Goods manufacturing practices (GMP).
• Good laboratory practices (GLP). 
• Good clinical practices (GCP).
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• ISO 9000, the national and international standards, respectively,.  
• ISO 14000, environmental management system (EMS)
3.2 The concepts of regulatory Standards
3.2.1 Good laboratory practices (GLP)
   In 1979 and 1980, an international group of experts established under the Special 
program on the Control of Chemicals  developed the “OECD Principles  of Good 
Laboratory Practice” (GLP), utilizing common managerial and scientific practices 
and experience from various national and international sources. These Principles of 
GLP were adopted by the OECD Council in 1981. Good Laboratory Practice (GLP) 
is  a quality system concerned with the organizational  process and the conditions 
under  which  non-clinical  health  and  environmental  safety  studies  are  planned, 
performed,  monitored,  recorded,  archived  and  reported.  The  purpose  of  these 
Principles of Good Laboratory Practice is to promote the development of quality test 
data. Comparable quality of test data forms the basis for the mutual acceptance of 
data  among  countries.  If  individual  countries  can  confidently  rely  on  test  data 
developed in other countries, duplicative testing can be avoided, thereby saving time 
and resources. The application of these Principles should help to avoid the creation 
of technical barriers to trade, and further improve the protection of human health and 
the environment (PMRA, 1998).
 3.2.2 Good clinical practices (GCP)
  Good  clinical  practice  (GCP)  is  an  international  ethical  and  scientific  quality 
standard for designing, conducting, recording, and reporting trials that involve the 
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participation  of  human  subjects.  Compliance  with  this  standard  provides  public 
assurance  that  the  rights,  safety,  and  well-being  of  trial  subjects  are  protected; 
consistent with the principles that have their origin in the Declaration of Helsinki, 
and that the clinical trial data are credible. They are listed to give an idea of the basic 
concepts of GCPs. Before becoming involved in clinical trials, one should have a 
good, working knowledge of GCP and understand that failure to comply with GCP 
can lead to disciplinary action including prosecution (ICH, 1996)
3.2.3 ISO 9000 & ISO 14000  
  In this part, the study will summarize the history and concept of the standards that 
are  mainly  adopted  by  the  Palestinian  Pharmaceutical  Companies.  These 
Standards are ISO 9000 and ISO 14000.
The  ISO  9000  and  ISO  14000  families  are  among  ISO's  most  widely  known 
standards  ever.  ISO  9000  has  become  an  international  reference  for  quality 
management requirements in business-to-business dealings, and ISO 14000 is well 
on the way to achieving as much, if not more, in enabling organizations to meet their 
environmental challenges (iso.org).
The  ISO  9000 family  is  primarily  concerned  with  "quality  management".  This 
means what the organization does to fulfill the customer's quality requirements, and 
applicable regulatory requirements, while aiming to enhance customer satisfaction, 
and   achieve  continual  improvement  of  its  performance  in  pursuit  of  these 
objectives. 
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        ISO certification is expected to help organizations to enhance quality and 
efficiency, improve communications, achieve competitive advantage and an increase 
in  market  share,  reduce  costs  and  achieve  a  higher  stock  price  (Magd  and 
Curry2003)
There is a very good reason why the EN-ISO 9000 series is the world’s best selling 
quality standard. If applied correctly, and sensibly, ISO series has the potential to 
generate  significant  and  sustainable  business  benefits  through  improved 
performance, reduced failure costs, and increased competitiveness (APIC, 1997).
The ISO 14000 family is primarily concerned with "environmental management". 
This means what the organization does to:
-  Minimize  harmful  effects  on  the  environment  caused  by  its  activities,  and  to
- Achieve continual improvement of its environmental performance.
1-    ISO 9000
   ISO 9000 comes from a non-governmentally run organization established 
in  1947 -  the International  Organization  for  Standardization  (ISO). The 
term “ISO” is derived from the Greek word "isos", meaning equal.  ISO 
standards are developed and administered by the International Standards 
Organization,  an  international  organization  to  which  approximately  one 
hundred countries belong.  
  ISO first published its quality standards in 1987, revised them in 1994, and then 
republished an updated version in  2000 . These new standards are referred to as 
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the "ISO 9000 2000 Standards".  ISO: 9000 series of standards deal with Quality 
Management Systems (QMS) for assuring quality of products and services and have 
become  international  reference  for  quality  requirements  in  business  to  business 
dealings.  These standards apply to all types of organizations - engineering, service, 
software, process industries (including pharmaceuticals).  ISO  9000 applies to all 
types of organizations. It doesn't matter what size they are or what they do. It can 
help both product and service oriented organizations  achieve standards of quality 
that are recognized and respected throughout the world. The term ISO  9000  refers 
to a set of quality management standards. 
.ISO 9000:2000 family contains 3 main standards:
- ISO 9000:2000 - QMS - fundamentals and vocabulary. 
- ISO 9001:2000 - QMS - requirements.
-  ISO 9004:2000 - QMS - guidelines for performance improvement.
   The  general  purpose  of  ISO  is  to  provide  standards  for  the  development, 
implementation  and  management  of  a  quality  management  system.  ISO  9000 
registration  is  best  viewed  as  a  management  tool  that  reaches  far  beyond  the 
province of "quality control" in a manufacturing environment, the application that 
first  comes to mind to many business people.  For ISO 9000 purposes, the term 
"quality" should be viewed as being synonymous with "excellence" and as applying 
to all segments of a company's operations, even those administrative functions that 
are  sometimes  not  viewed as being part  of  the overall  goals  of  the company in 
meeting its customers' needs. When used properly, ISO 9000 is a great management 
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tool to promote excellence throughout all functions or all enterprises in all sectors of 
the economy,  from manufacturing companies to service businesses to health care 
providers. The  ISO 9000 quality  management  systems  (QMS) standards  are  not 
specific to products or services, but apply to the processes that create them. 
  The essence of ISO 9000 is for a company to "document what it does and do 
what it documents."  The documentation is developed through the facilitation 
process and consists essentially of work instructions and quality and operational 
procedures designed to assure that goods and services are developed, created 
and  delivered  in  a  consistent  manner  that  reflects  the  quality  goals  of  the 
organization.
Procedures and quality systems are necessary to maintain the consistency of the 
company's products or services and that these procedures and systems are properly 
and timely documented."  ISO 9000 is sweeping the world. It is rapidly becoming 
the most  important  quality  standard,  because it  controls  quality,  it  saves  money, 
customers expect it, and competitors use it.
  The principles of ISO 9001:2000 are universally applicable, but the application is 
specific  to  product,  process  size  of  organization  and  competence  levels  of 
employees.  As  such,  the  application  of  ISO 9001:  2000  for  the  pharmaceutical 
industry is totally different from engineering software or service organization.
 ISO 9001:2000 QMS is based on the following generic principles: 
• Customer focus to meet and expectations of the society 
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• Leadership to provide direction. 
• Involvement of people to produce high quality medicines 
• Process approach to improve efficiency and effectiveness of processes 
• Systems approach to decision making to have a base for right decisions. 
• Mutually beneficial supplier relationship to get the best from suppliers. 
A few additional requirements for a pharmaceutical organization to be considered 
while developing a QMS are as follows:
Quality  policy  shall  include  a  statement  on  hygiene,  environmental  control  and 
product  security  apart  from  meeting  customer  expectations  and  organization's 
objectives.
The  QMS  of  pharmaceutical  organizations  should  include  good  manufacturing 
practices  apart  from requirements  of  ISO 9001:2000.  The  requirements  of  GMP 
became a part of drug rules in the year 1984. These must be included as a part of the 
QMS. Similarly, the practice of purchasing shall cover that the organization shall not 
employ subcontractors without prior approval of purchaser.
Where raw materials and packing materials are supplied to customer, it is important 
that  containers and packaging are adequately labeled.  Special  precautions,  if  any 
supplied by the customer, shall be followed.
The product traceability is a specified requirement for the pharmaceutical  sector. 
The  method  adapted  is  use  of  batch  manufacturing  records.  Raw material  batch 
number shall be identified in the batch control record where specified by purchasers. 
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2- ISO 14000
ISO  14000,  released  in  1996,  is  a  global  series  of  environmental  management 
systems (EMS) standards, providing a framework for organizations to demonstrate 
their commitment to environmental responsibility. 
  An EMS enables an organization to control the environmental aspects and impacts 
of its activities, products and services by establishing targets and objectives related 
to  identified  environmental  management  goals.  Once implemented,  an EMS will 
improve compliance with legislative and regulatory requirements, reduce exposure 
to liability, prevent pollution, reduce waste and create a more positive public image. 
ISO 14001 is the specific standard that provides guidance for the development of a 
comprehensive environmental management system (EMS). The EMS is based on the 
Total Quality Management (TQM) business concept of continuous improvement, or 
the Plan-Do-Check-Act cycle in which a procedure is developed, implemented, and 
then reviewed and improved upon if necessary. This cyclic nature ensures that the 
EMS is both proactive and continuously improving.
   Organizations that register to ISO 14001, the most important of the ISO 14000 
standards,  demonstrate  sound  environmental  management  practices,  are  able  to 
prevent  environmental  disasters  and government  sanctions,  and experience  fewer 
regulatory  audits  by  correcting  environmental  problems.  ISO  14000  supporting 
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documents  include  environmental  labeling,  life-cycle  assessment,  environmental 
aspects in product standards, and environmental performance evaluation. 
   The expectation is that eventually 14001 will follow suit, and companies without 
certification will not be able to engage in international trade. This has contributed to 
the large numbers of European and Asian companies certifying their EMSs under 
the standard.  However,  in  the US, companies  have been both slow to adopt  the 
standard and highly critical of its potential value. 
  According to Poksinska, Dahlgaard and Eklund, (2002), ISO 14000 is based on the 
concept that better environmental performance can be achieved when environmental 
aspects are systematically identified and managed. ISO, (1998), states that potential 
benefits  for  ISO 14001 users  can  be achieved  such as,   reduced costs  of  waste 
management,  savings  in  the  consumption  of  energy  and  materials,  an  enhanced 
corporate image, regulatory cost savings, more effective supply chain management, 
improved customer relationships, and increased market competitiveness.
3.3 The Concepts of Quality Assurance, GMP, and   
Quality Control
The language of quality management is chock full of acronyms and abbreviations: 
ISO and  QS,  TQM and  CI,  SPC and  SQM.  When  it  comes  to  medical  device 
manufacturing, however, the initials to keep in mind are GMP.
  According to EC Directive, FDA, and WHO GMP regulations and guidelines, the 
basic  concepts  of  Quality  Assurance,  Good  Manufacturing  Practice  and  Quality 
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Control are interrelated aspects of quality management. EC directives 91/356/EEC 
and 91/412/EEC stated that: To ensure quality, all pharmaceutical manufacturers are 
required  to  establish  and  implement  an  effective  pharmaceutical  QA  system, 
involving  the  active  participation  of  the  management  and personnel  of  different 
services involved. To assess the effectiveness of this QA system and ensure that it 
follows  good  manufacturing  practice  (GMP),  regular  audits  must  be  performed. 
Audits may be performed by the manufacturer on itself (internal), or on its vendors 
(external).  Alternatively,  audits  may  be  conducted  on  a  manufacturer  by  its 
customers or by a regulatory body (governmental authority).
GMP, QA, and QC, are described here in order to emphasize their relationship and 
their  fundamental  importance  to  the  production  and  control  of  pharmaceutical 
products.
3.3.1 Quality Assurance
"Quality assurance" is a wide-ranging concept covering all matters that individually 
or  collectively  influence  the  quality  of  a  product.  It  is  the  totality  of  the 
arrangements made with the object of ensuring that pharmaceutical products are of 
the quality required for their intended use. Quality assurance therefore incorporates 
GMP and other  factors,  including  those  outside  the  scope  of  this  guide  such as 
product design and development.
   The system of quality assurance appropriate to the manufacture of pharmaceutical 
products should ensure that.
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(a) Pharmaceutical products are designed and developed in a way that takes account 
of  the  requirements  of  GMP and  other  associated  codes  such  as  those  of  good 
laboratory practice (GLP) and good clinical practice (GCP). 
(b) Production and control operations are clearly specified in a written form and 
GMP requirements are adopted.
(c) Managerial responsibilities are clearly specified in job descriptions. 
(d)  Arrangements  are  made  for  the  manufacture,  supply,  and  use  of  the  correct 
starting and packaging materials.
(e)  All  necessary  controls  on  starting  materials,  intermediate  products,  and  bulk 
products and other in-process controls, calibrations, and validations are carried out.
(f) The finished product is correctly processed and checked, according to the defined 
procedures.
(g) Pharmaceutical products are not sold or supplied before the authorized persons 
have  certified  that  each  production  batch  has  been  produced  and  controlled  in 
accordance  with  the  requirements  of  the  marketing  authorization  and  any  other 
regulations  relevant  to  the  production,  control  and  release  of  pharmaceutical 
product.
(h)  Satisfactory  arrangements  exist  to  ensure,  as  far  as  possible,  that  the 
pharmaceutical  products  are  stored  by  the  manufacturer,  distributed,  and 
subsequently handled so that quality is maintained throughout their shelf-life.
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(i)  There  is  a  procedure  for  self-inspection  and/or  quality  audit  that  regularly 
appraises the effectiveness and applicability of the quality assurance system.
3.3.2  Good  Manufacturing  Practice  for  Medicinal  Products 
(GMP) 
Good Manufacturing Practices were officially introduced in 1976 in the Code of 
Federal Regulations, Title 21 (CFR 21) Parts 210 and 211. CFR 21 stipulates that 
written procedures must be followed in pharmaceutical manufacturing.
Failure  to  comply  with  this  regulation  is  a  criminal  act.  Standard  Operating 
Procedures (SOPs) are the written procedures that firms create to ensure that they 
are  adhering  to  cGMPs.  SOPs  not  only  provide  direction  to  operators  and 
technicians  in  how to  perform their  jobs  correctly,  they  also  serve  as  guidance 
documents to help a firm prove it is committed to cGMP compliance.
   Good manufacturing practice is that part of quality assurance which ensures that 
products  are  consistently  produced  and  controlled  to  the  quality  standards 
appropriate  to their  intended use and as required by the marketing authorization. 
GMP  rules  are  directed  primarily  to  diminishing  the  risks,  inherent  in  any 
pharmaceutical production that cannot be prevented completely through the testing 
of final products. Such risks are essentially of two types: cross-contamination (in 
particular  by unexpected  contaminants)  and mix-ups  (confusion) caused by false 
labels being put on containers. 
Under GMP guidance:
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(a) All manufacturing processes are clearly defined, systematically reviewed in the 
light  of  experience,  and  shown  to  be  capable  of  consistently  manufacturing 
pharmaceutical  products  of  the  required  quality  that  comply  with  their 
specifications.
(b) Critical steps of manufacturing processes and any significant changes made to 
the processes are validated.
(c) All necessary facilities are provided, including: 
(1) Appropriately qualified and trained personnel.
(2) Adequate premises and space.
(3) Suitable equipment and services.
(4) Correct materials, containers, and labels.
(5) Approved procedures and instructions.
(6) Suitable storage and transport.
(7) Adequate personnel, laboratories, and equipment for in-process controls under 
the responsibility of the production management. 
(d)  Instructions  and  procedures  are  written  in  clear  and  unambiguous  language, 
specifically applicable to the facilities provided.
(e) Operators are trained to carry out procedures correctly.
67
(f)  Records  are  made  (manually  and/or  by  recording  instruments)  during 
manufacture  to  show  that  all  the  steps  required  by  the  defined  procedures  and 
instructions have in fact been taken and that the quantity and quality of the product 
are as expected; any significant deviations are fully recorded and investigated.
(g)  Records  covering  manufacture  and  distribution,  which  enable  the  complete 
history of a batch to be traced, are retained in a comprehensible and accessible form.
(h) The proper storage and distribution of the products minimizes any risk to their 
quality.
(i) A system is available to recall any batch of product from sale or supply.
(j) Complaints about marketed products are examined; the causes of quality defects 
investigated, and appropriate measures taken in respect of the defective products and 
to prevent recurrence.
   GMP  provides  the  general  basics  to  determine  the  minimum  acceptable 
requirements for the production at Good products, covering all the activities related 
to  the  production  process.  These  basics  are  divided  into  several  categories: 
Organization  and  Personnel,  Buildings  and  Facilities,  Equipment,  Control  of 
Components and Drug Product Containers and Closures,  Production and Process 
Controls,  Packaging and Labeling Controls,  Holding and Distribution,  Laboratory 
Control, Records and Reports, and Returned Drug Products. 
3.3.3 Quality Control
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   Quality control is the part of GMP concerned with sampling, specifications, and 
testing  and  with  the  organization,  documentation,  and  release  procedures  which 
ensure that the necessary and relevant tests are actually carried out and that materials 
are not released for use or products released for sale or supply, until their quality has 
been  judged  to  be  satisfactory.  Quality  control  is  not  confined  to  laboratory 
operations  but  must  be  involved  in  all  decisions  concerning  the  quality  of  the 
product.
 The independence of quality control from production is considered fundamental. 
The  quality  control  department  should  be  independent  of  other  departments  and 
under the authority of a person with appropriate qualifications and experience, who 
has one or several control laboratories at his or her disposal.  Adequate resources 
must be available to ensure that all the quality control arrangements are effectively 
and reliably carried out. The basic requirements for quality control are summarized 
as follows:
(a)  Adequate  facilities,  trained  personnel  and  approved  procedures  must  
be  available  for  sampling,  inspecting,  and  testing  starting  materials,  packaging 
materials, and intermediate, bulk, and finished products, and where appropriate for 
monitoring environmental conditions for GMP purposes.
(b) Samples of starting materials, packaging materials, intermediate products, bulk 
products and finished products must be taken by methods and personnel approved of 
by the quality control department.
(c) Test methods must be validated.
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(d)  Records  must  be  made  (manually  and/or  by  recording  instruments) 
demonstrating that all the required sampling, inspecting, and testing procedures have 
actually  been  carried  out  and  that  any  deviations  have  been  fully  recorded  and 
investigated.
(e) The finished products must contain ingredients complying with the qualitative 
and  quantitative  composition  of  the  product  described  in  the  marketing 
authorization;  the  ingredients  must  be  of  the  required  purity,  in  their  proper 
container, and correctly labeled.
(f)  Records  must  be  made  of  the  results  of  inspecting  and  testing  materials  
and  intermediate,  bulk,  and  finished  products  against  specifications;  product 
assessment  must  include  a  review  and  evaluation  of  the  relevant  production 
documentation and an assessment of deviations from specified procedures.
(g) No batch of product is to be released for sale or supply prior to certification by 
the  authorized  person(s)  that  it  is  in  accordance  with  the  requirements  of  the 
marketing authorization. In certain countries, by law, the batch release is a task of 
the authorized person from the production department together with the authorized 
person from the quality control department.
(h) Sufficient samples of starting materials and products must be retained to permit 
future examination of the product if necessary; the retained product must be kept in 
its final pack unless the pack is exceptionally large.
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  The quality control department as a whole will also have other duties, such as to 
establish,  validate,  and  implement  all  quality  control  procedures,  to  evaluate, 
maintain,  and  store  the  reference  standards  for  substances,  to  ensure  the  correct 
labeling of containers of materials and products, to ensure that the stability of the 
active pharmaceutical  ingredients and products is monitored,  to participate in the 
investigation of complaints related to the quality of the product, and to participate in 
environmental monitoring. All these operations should be carried out in accordance 
with written procedures and, where necessary, recorded.
   Assessment of finished products should embrace all relevant factors, including the 
production conditions, the results of in-process testing, the manufacturing (including 
packaging)  documentation,  compliance  with  the  specification  for  the  finished 
product, and an examination of the finished pack. Quality control personnel must 
have access to production areas for sampling and investigation as appropriate.
According  to  Broun,  (1994),  pharmaceuticals  of  low quality,  either  imported  or 
locally produced, should not reach the population. This calls for a system of quality 
control (including a national or regional control laboratory)  and strict  criteria for 
enforcement of the quality of distribution (storage, transport, and packaging). The 
approach recommended by WHO is to restrict  drug purchasing to drug suppliers 
who follow Good Manufacturing Practices (GMP) in production facilities, both for 
imported and locally produced goods.  Local  producers should proceed as fast  as 
possible  towards  GMP standards  and not  be  awarded  a  "right"  to  produce  sub-
standard drugs because of their nationality.  However, upgrading of manufacturing 
standards often has to be staged over time. Regulations regarding quality must be 
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enforced  by  a  well-organized  and  trained  inspection  administration,  independent 
from commercial pressure. 
Finally, the concepts of QA, GMP and QC, are identified by WHO, EC directive, 
FDA, and all  other  national  and/  or  international  organization  of pharmaceutical 
manufacturing regulations. All the international and national regulations have the 
same  identification  of  these  concepts  with  minor  differences.  Finally,  to  ensure 
quality, all pharmaceutical manufacturers are required to establish and implement an 
effective  pharmaceutical  QA  system,  involving  the  active  participation  of  the 
management and personnel of different services involved. 
3.4 Relationship between ISO certification and GMP 
compliance.
All the six Palestinian pharmaceutical companies have ISO 9000 and five of them 
have ISO 14000 certificates,  but no one has GMP. There are many international 
companies  having  both  ISO Certificates  and GMP compliance,  or  one  of  them. 
There are rising questions about the two systems, such as, the relationship between 
GMP and ISO.
Both GMP and ISO are quality systems in their  own right. As the revised GMP 
became final in June 1997, the two systems became closer in how they are written 
and how a company should be achieving quality. There is, however, a real difference 
between GMP compliance and ISO certification. Schwartz, (1998), summarized the 
similarities and differences between ISO series and GMP certificates, as follows:
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The  GMPs  are  a  regulatory  requirement  mandated  by  law,  and  if  you  are 
manufacturing medical products or devices, you must be in compliance with these 
regulations.  ISO,  on  the  other  hand,  is  a  voluntary  certification  obtained  by  a 
company when they determine that the certification is beneficial to their operations 
and/or marketing strategies. The ISO 9000 standard is not specific for any industry 
or service, while GMP is specific for medical device, drug, blood bank, and low acid 
canned food industries.
The revised GMP includes design review, management review, vendor qualification, 
and corrective and preventive action. ISO is precision, while GMP is compliance. 
Precision is the ability to repeat a task time after time and obtain the same results. 
An ISO certification audit certifies that your system is in place, assuring capability 
of providing precision. If precision cannot be achieved, policies and procedures will 
address these issues.
The  fundamental  difference  between  GMP  and  ISO  is  that  both  have  different 
agendas.  Once  this  is  understood,  the  road  to  achieving  ISO  certification  for  a 
medical device company (who is in GMP compliance) will be much easier, faster, 
and less expensive.
Finally,  implementation  of  a  comprehensive  quality  systems  model  for human 
pharmaceutical  products  will  facilitate  compliance  with  international  regulations 
and  standards.  The  central  goal  of  a  quality  system  is  to  ensure  consistent 
production of safe and effective products and that these activities are sustainable.  
Quality professionals  are  aware that  good intentions  alone will  not  ensure good 
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products.  A robust quality system will promote process consistency by integrating 
effective  knowledge-building mechanisms  into daily operational  decisions. When 
fully developed and effectively managed, a quality system will lead to consistent, 
predictable  processes  that  ensure  that  pharmaceuticals  are  safe,  effective,  and 
available for the consumer.
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CHAPTER FOUR
Research Methodology
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4.1 Introduction
 The purpose of any research study is to investigate a solution for a given problem 
through the application of scientific approaches. These approaches are developed in 
order to gather relevant,  reliable and unbiased information to the asked question 
about that particular problem. This implies that the research is started by identifying 
a clear and specific problem that needs to be resolved. The problem is represented 
by a question to be answered through the application of scientific approaches or 
methods.  The  approach  will  include  many  steps  to  be  taken  for  gathering  and 
analyzing  the data,  determining  the associated  factors,  providing answers  to  the 
questions, and taking the necessary corrective measures.
The main question of this research is related to the impact of quality management 
systems on cost and competitiveness in Palestinian pharmaceutical companies  (is  
the  investment  in  quality  worthwhile?).  Therefore,  this  chapter  will  start  with 
discussing related research design and methodological issues and then decide the 
appropriate research techniques to find the answers for the questions raised by this 
study.
4.2 Research Methodology Selection
 The basic concern of this study is to investigate the impact of quality on cost and 
competitiveness  in  Palestinian  pharmaceutical  companies,  by  investigating  the 
understanding of the quality concept and understanding and knowledge about the 
cost and benefits of quality between middle level and top level managers. So, there 
is  a  need  for  appropriate  approach  to  be  carefully  designed,  either  quantitative 
and/or qualitative, taking into consideration collecting, processing and analyzing the 
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data very carefully. Selecting the appropriate methodology depends on the purpose 
of the research, the process, and the desired outcomes. Downey and Ireland, (1979) 
stated that: "Methodologies are neither appropriate nor inappropriate until they are 
applied to  a specific  research problem.  This perspective treats  methodologies  as 
tools for inquiry; each inquiry requires careful selection of the proper tools".   
4.2.1 Research Tools
The collected data were both primary and secondary. Secondary data were collected 
through literature  review and other  published and unpublished reports.  Whereas, 
primary data were collected by using two tools, interviews with general managers 
of  the  Palestinian  pharmaceutical  companies,  executive  manager  of  Union  for 
Palestinian Pharmaceutical Manufacturers (UPPM), and Quality Control Director in 
Palestinian Ministry of Health. The second tool was a questionnaire for managers 
and supervisors of each of four Palestinian pharmaceutical companies. 
4.2.2 Questionnaire Design 
    The questionnaire was designed:
- To investigate the management commitment to quality and concept of the 
quality awareness.
-  To investigate if there is a resistance to change toward quality management 
systems  implementation  which  may  affect  employees  performance  and 
productivity
-    To investigate the benefits of quality.
-  To investigate the impact of quality on competitiveness. 
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-   To investigate the reasons of complying with international standards and 
producing according to requirements.
  The questionnaire was designed according to three types of scales, nominal scales 
(Part one), likert scales (Part two), and ordinal scale (Part three). 
- Part one consists of two questions about the position and department. 
- Part  two  contains  of  58  questions  divided  into  four  categories,  quality 
concept and organization commitment for quality, cost of quality related to 
employees resistance,  tracking cost of conformance and nonconformance, 
benefits of quality, and impact of quality on competitiveness.
- Part Three contains one question to investigate the most important and least 
important reason of implementing quality management systems (ISO9000 & 
14000) and complying with GMP requirements.
4.2.3 Face to Face Interviews 
   The  main  purpose  of  interviewing  top  level  mangers  of  the  pharmaceutical 
companies was to collect more information about the impact of quality management 
systems  on  these  companies  and  how  companies  can  benefit  of  implementing 
effective quality management systems and complying with international standards 
and regulations.
The purpose of interviewing some experts  in Palestinian pharmaceutical  industry 
was to investigate the effect of quality management systems on the pharmaceutical 
industry and if the companies could benefit from these implementations.
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4.3 Study Population and Sample
The  population  represents  managers  and  supervisors  of  four  out  of  six 
pharmaceutical companies in Palestine located in the West Bank (5 companies), and 
Gaza Strip (one company). Because the population is not large, the sample of the 
study represents the population. The sample is limited to managers and supervisors 
of  these  four  West  Bank  -located  companies  (Birzeit  Pharmaceutical  Company, 
Jerusalem  Pharmaceutical  Company,  Pharmacare  Company,  and  Beit  Jala 
Pharmaceutical Company). The total number of managers and supervisors is about 
70 (40 managers and 30 supervisors). But the respondents to the questionnaire were 
47 (31 managers and 16 supervisors), as classified in Table (3). 
Table (3);  Respondents' classifications (position and departments).
                  Position 
Department
Managers Supervisor
1. Production 4 6*
2. Finance 3 -
3. Sales and Marketing 6 3
4.  Quality  control/ 
Assurance
6 5
5. R&D 4 1
6. Others 9 -
Total 31 16
* The collected questionnaires are (6), but one of them was dropped out.
The  respondents  of  the  first  five  departments,  Production,  Finance,  Sales  and 
marketing, Quality control and or assurance, and R&D, represent the majority of 
respondents (81%).  All managers of production, marketing,  quality control,  and 
R&D answered the questionnaire.    
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4.4 Goodness of data
4.4.1 Validity: 
All  instruments  of  the research  were used in  previous  studies;  moreover,  before 
distributing the questionnaire to respondents, a pilot study was conducted by sending 
the questionnaire to five experts in the pharmaceutical industry, to Professor Nidal 
Sabri and to the supervisor (Dr. Munther Nijim), who advised introducing changes 
and edits  to achieve high validity.  So, the questionnaire is expected be valid for 
measuring the variables.
4.4.2 Reliability:
To  check  the  reliability  of  the  questionnaire,  chronbach's  alpha  was  calculated 
(0.890)  which  is  implying  that  the  results  are  acceptable,  and  there  is  internal 
consistent reliability.
4.5 Hypothesis
Two hypotheses will be tested in the research to find the relation between effective 
quality management systems, cost and competitiveness.
To accomplish the purpose of this  study,  the following null  hypothesis  (H0)  and 
alternative hypothesis (Ha) have been stated.
1. H01:  There  is  no  correlation  between  quality  management  systems 
implementation in pharmaceutical companies and cost.
2. Ha1:  There  is  a  correlation  between  quality  management  systems 
implementation in pharmaceutical companies and cost. 
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3. H02:  There  is  no  correlation  between  quality  management  systems 
implementation in pharmaceutical companies and competitiveness.
4. Ha2:  There  is  a  correlation  between  quality  management  systems 
implementation in pharmaceutical companies and competitiveness. 
4.6 Data Analysis
The  purpose  of  data  analysis  was  to  answer  the  research  question  (problem 
statement) which was stated in section 1.4 of chapter one.  The question was "To 
what  extent  managements  are  committed  to  improving  quality  of  Palestinian 
Pharmaceuticals and what is the correlation between effective quality management 
systems implementation,  Cost,  and competitiveness  in Palestinian pharmaceutical 
companies?"
4.6.1 Data Management
4.6.1. a)  Editing:  All received questionnaires were checked to make sure that 
every  question  was  properly  answered  and  there  are  no  missing  data.  From 47 
received questionnaires, one questionnaire was dropped out because more than 25% 
of the statements was either improperly answered or left without answers.
 4.6.1.b) Data Entry: Excel sheets were used for data entry, because it is easy to 
transfer  the  collected  data  to  a  data  analysis  program  such  as  SPSS.  After 
completing  data  entry,  the  data  was  transferred  to  Scientific  Package  of  Social 
Science (SPSS) version 12.0 programs for data analysis and testing.  
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4.6.2 Statistical Analysis
  After transferring the data from excel sheets to SPSS sheets, proper coding and 
scoring were done for each question to make the proper analysis. The main part of 
the data  (q3 – q60) was collected as likert  scale  (from (1) strongly agree to (5) 
strongly disagree) so, each answer was converted into score (1= 100, 2= 25, 3= 75, 
5= 0), except questions 14, 15, 16, and 21, which were oppositely scored. Then a cut 
point was selected to be (60), which means that the accepted score to each statement 
must be more than sixty to be significant for measuring the phenomena. The next 
step was gathering the 58 statements in 5 variables according to the relationships 
and  correlations  between  each  group of  questions.  The  five  new variables  were 
Quality concept and management commitment, Quality cost related to employees' 
resistance, Cost of Conformance and Nonconformance tracking, Benefits of Quality, 
and Impact  of Quality  on Competitiveness.   The required statistic  analyses  were 
done for the 58 statements and the generated five new variables, like frequencies, 
means, and other related tests.
  The  third  part  of  the  questionnaire  was  designed  as  ordinal  scale,  by  asking 
respondents  to  rank  the  reasons  of  complying  with  international  standards  and 
regulations according the importance of each item, 1 is the most important and 6 is 
the least important. Then the frequencies and means of answers were calculated. 
  Finally,  to  check  if  there  are  significant  differences  in  the  answers  between 
managers and supervisors or between respondents from different departments, the 
second and third part of the questionnaire were correlated to the first part which 
consists   of two questions, position of the respondent and the department he works 
82
in. To find if there are significant differences in answers between respondents from 
the  different  companies,  answers  were  al  correlated  to  the  company  that  every 
respondent work for.
    The analysis and the findings were presented in different tables and figures in 
chapter five
4.8 Hypothesis Testing
 The two hypotheses were tested in the research, by using One Sample T- test. They 
are stated by the null hypothesis (H0) and alternative hypothesis (Ha). The concept 
of quality and management commitment was also tested to measure the degree of 
awareness  about  quality  concept  and  management  commitment  to  quality 
improvement. 
 The mean, standard deviation and standard error of each variable were calculated in 
comparison with the cut point. By using SPSS program the population is expected to 
be infinity so the program neglects the effect or power of the population and the 
proportion of the sample. But, in this case, the population is finite (70 managers and 
supervisors). To improve the power of the measurements, the population effect was 
taken into consideration by calculating (t) value using the mathematical equations:
H0: P = P0 = 60
Ha: P >P0 > 60
 (P) is the proportion of the population. ∧P  is the mean of the result.
 ; Where n = sample size = 46, N = the population size = 
70, and σ is the standard deviation.
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Then (t) test statistic was used to decide if the hypothesis is rejected or accepted:
∧
−
=
∧
P
PPt
σ
The level of significance for the test  was selected at α = 0.05. From the normal 
distribution table the value corresponding to (t0.05) was found to be (1.645). The 
hypothesis will be rejected if the computed (t) < 1.645. However, the calculated (t) 
values were significant enough which made no need to recalculate (t) by using the 
equation.
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CHAPTER FIVE
Findings and Results of the Study
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5.1 Introduction
   The questionnaire and the structured interviews were designed to get the proper 
investigation by answering the stated study question in Chapter one (section 1.4). 
So,  the  findings  and  results  were  collected  to  answer  of  the  following  central 
questions:
• To  what  extent  managements  are  committed  to  improving  quality  of 
Palestinian Pharmaceuticals?
•  What  is  the  correlation  between  quality  management  systems 
implementation and Cost?
• What  is  the  correlation  between  quality  management  systems 
implementation  and  competitiveness  in  Palestinian  pharmaceutical 
companies?
The  findings  of  the  questionnaire  were  collected  from  managers  and 
supervisors responding as follows:
• Position and departments that respondents fill and work in.
• The concept of quality and management commitment toward improving 
quality.
• The costs of Quality incurred as a result of employees resistance
• Cost conformance and nonconformance  tracking Concept
• The benefits of quality 
• The impact of quality on competitiveness
• The  reasons  of  implementing  quality  management  systems  and 
complying with international standards and regulations.
86
5.2 Companies, Positions and Departments
The analysis  of data,  gathered through the questionnaire,  revealed the following 
results in terms of position (manager or supervisor), and department (production, 
finance, sales and marketing, R&D, Quality control / assurance, others).
Table (5.1), the respondents' distribution between the four companies
Company* Number  of 
respondents
% Valid % Cumulative %
Company 1 14 30.4 30.4 30.4
Company 2 10 21.7 21.7 52.2
Company 3 12 26.1 26.1 78.3
Company 4 10 21.7 21.7 100
Total 46 100% 100%
* The numbers were used instead of names to avoid any inconvenience with  
companies' names.
Table (5.2): Positions of respondents  
Position Number  of 
respondents
% Valid % Cumulative %
Manager 31 67.4 67.4 67.4
Supervisor 15 32.6 32.6 100
Total 46 100 100
Table (5.3) Respondents' distribution in companies' departments.
Department Number  of 
respondents
% Valid % Cumulative %
Production 9 19.6 19.6 19.6
Finance 3 6.5 6.5 26.1
Sales and Marketing 9 19.6 19.6 45.7
Quality  control/ 
assurance
11 23.9 23.9 69.6
R&D 5 10.9 10.9 80.4
Others 9 19.6 19.6 100
Total 46 100 100
Table (5.4) Distribution of managers and supervisors according to their departments.
Position Production Finance Sales& 
Marketing
Q C & 
QA
R&D Others Total
Manager 4 3 6 5 4 9 31
Supervisor 5 0 3 6 1 0 15
Total 9 3 9 11 5 9 46
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The previous four tables show the following characteristics of respondents:
1. The total number of respondents was 46 from four companies. The numbers of 
respondents  of  the  four  companies  are  varied  as  follows:   Respondents  of 
company 1 are 14 (30.4%) and company 3 are 12 (26.1%) where as respondents 
of companies 2 and 4 are 10 for every one (21.7) for each company.  These 
variations may be due to the organizational structure for each company.
2. The majority of respondents were managers (67.4%), whereas the supervisors' 
percentage was (32.6%)
3. The majority of respondents are working in the key operating departments such 
as  (Production,  R&D, Quality  control/  assurances,  Sales  and marketing,  and 
finance) (80.4%).
5.3 Quality concept and management commitment for 
improving quality
To  investigate  the  awareness  about  the  quality  concept  and  management 
commitment  for  improving  quality,  14  related  statements  were  included  in  the 
questionnaire. After collecting the data, means of the 14 statements were calculated. 
Then the 14 statements were recoded as one variable called (Quality concept), then 
the mean of means of the 14 statements' answers was calculated as the mean of the 
quality concept.
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Table (5.5.a): The quality concept and management commitment for improving 
quality
Statement N Mean Std. 
Deviation
Std. 
Error 
Mean
1 Employees in my department are adequately informed 
about the quality standards that apply to their jobs
46
84.24 19.263 2.840
2 Employees in my department are adequately informed 
about the quality objectives of our department.
46
85.87 18.747 2.764
3 We have the technical and managerial skills necessary to 
measure the quality of work.
46
84.24 17.763 2.619
4 The quality improvement process is considered an 
important priority by Senior Management
46
87.5 18.066 2.663
5 The quality improvement process is considered an 
important priority b y Myself
46
92.39 11.630 1.7148
6 The  quality improvement process is considered an 
important priority b y My department employees
46
80.43 20.353 3.001
7 Too much emphasis is placed upon quality of work 
produced rather than its quantity
46
73.37 24.382 3.595
8 Quality improvement is viewed as a long term 
commitment, not to be compromised by short- term 
financial goals
46
80.98 21.848 3.221
9 My department's emphasis on quality has resulted in 
measurable improvement in our products and services
46
83.15 16.712 2.464
10 Management commitment to quality is apparent in what 
we do on day-to- day basis
46
71.20 20.390 3.006
11 The top management and the middle level management 
are implementing programs and processes for quality 
improvement
46
76.63 20.001 2.949
12 The top and middle level management are providing tools 
and resources required for quality improvement.
46
73.37 18.561 2.737
13 The company feels more confidence that the company's 
products meet relevant regulatory requirements
46
84.78 17.856 2.633
14 The company often sacrifices the quality of products in 
order to cut costs
46
43.48 36.68 5.408
QUALITY CONCEPT AND MANAGEMENT 
COMMITMENT FOR IMPROVING QUALITY
46 79.62 12.329
1.818
The previous table shows that the majority of respondents responded positively to 
the statements. The response to statement (14)  " The company often sacrifices the 
quality of products in order to cut costs" had different direction from the other 13 
statements,  which means that  the direction  of respondents was toward company 
commitment  to  quality,  but  the  direction  of  response  to  statement  was  that 
companies  some  times  scarifies  quality  to  cut  costs.  This  might  be  due  to 
misunderstanding the statement or it might be intentional response.
By comparing the achieved results ( ∧P ) with the cut point (ρ0 = 60), the results 
reveal that only about (13%) of results ( ∧P ) are less than (ρ0), and the mean of the 
14 statements' means is (79.62). To test the significance of the results (one sample 
T- Test) was calculated, as summarized in the following table:
In the table (5.5.b), (t) calculated = 10.793; at 95% confidence is grater than (t) 
tabulated (1.645), which means that there is a correlation between the statements 
and that the results are significant, consequently it indicates:
1. The quality concept is well understood
2. There is managements' commitment for improving quality.
5.4 Cost of Quality incurred as a result of employees' 
resistance.
The  study tried  to  investigate  the  concept  of  quality  cost  by  answering  indirect 
questions.  The cost  of  quality  wasn't  measured  as calculations  of investments  in 
quality improvement, but the effect of quality management systems on the culture 
and employees performance so as to investigate if there was resistance for change 
(ie.  Implementing  quality  management  systems  and  operating  according  to 
Table (5.5.b) One-Sample Test
10.793 45 .000 19.61957 15.9582 23.2809Quality Concept
t df Sig. (2-tailed)
Mean
Difference Lower Upper
95% Confidence
Interval of the
Difference
Test Value = 60
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standards).  So,  the  results  revealed  that  there  was  some  resistance  or 
misunderstanding to some quality regulations and aspects. The investigation of the 
cost of quality incurred as a result of employees' resistance was represented by three 
statements  in  the  questionnaire.  The  three  statements  were  converted  into  one 
variable  called  (Quality  Cost  incurred as a  result  of  employees'  resistance),  then 
mean of the 3 means was calculated and tested to check its significance.
The mean of the three statements means is 55.4349 % of the total score (100) which 
mean that the direction of responses of the statements was not identical and this also 
means that the correlation between the quality and costs resulting from resisting the 
change and complying with regulations and international standards is not clear. This 
may be due to  the respondents understanding  of statements  or  the resistance to 
change might not be tracked or assessed as a result of quality management systems. 
See, Table (5.6.a)
Table (5.6.a ): Quality cost related to employees resistance
ISO 9000, and 14000 certificates and 
complying with GMP requirements increase 
costs as follows.
N Mean St. 
Deviation
St. Error
15 Operating according to ISO and GMP requirements 
force employees to spend a lot of time on 
documentation and inspection which can be used for 
production. 46 67.93 29.185 4.303
16 The continuous concentration on the rules and 
requirements of ISO and GMP, causes employees to 
feel inconvenience, which affects there productivity 
and performance. 46
46.19
6 28.366 4.182
17 Some employees feel that a lot of steps used according 
to standards are not necessary, and they some times 
resist doing them. 46 52.17 24.623 3.630
QUALITY COSTS RELATED TO EMPLOYEES 
RESISTANCE 46 55.43 20.429 3.012
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  The frequencies and percentages of respondent answers were also, calculated to 
build more information about this factor. 
Table (5.6.b): Percentages of answers of statements (15,16,and 17)
ISO 9000, and 14000 certificates and 
complying with GMP requirements increase 
costs as follows.
St. 
Agree
Agree Neutral Disagree St. 
Disagree
Operating according to ISO and GMP 
requirements force employees to spend a lot 
of time on documentation and inspection 
which can be used for production. 26.09 45.65 6.52
17.39 4.35
The continuous concentration on the rules and 
requirements of ISO and GMP, causes 
employees to feel inconvenience, which 
affects there productivity and performance. 8.70 21.74 23.91
36.95 8.70
Some employees feel that a lot of steps used 
according to standards are not necessary, and 
they some times resist doing them.
4.35
34.78 30.43
26.09 4.35
Figure  (1): Percentages of answering to questions (15,16, & 17)
Cost related to change resistance
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5.5 Cost of Conformance and non-conformance Awareness
Eight statements were used to investigate the cost of quality concept. Every one of 
the  eight  statements  was  asked  to  investigate  if  the  managers  and  supervisors 
understand the concept of quality cost as cost of conformance and nonconformance, 
if they can analyze the cost and benefit of quality, and finally, if they can measure 
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the impact of poor and high quality on costs, competitiveness, sales, profits and 
customer loyalty. 
Table (5.7.a):  Cost conformance and nonconformance concept.
Statement N Mean St. 
Deviation
St. 
Error
18 The cost of poor quality in short- term are due to 
scrap rate, rework, defects, etc. 46 63.04 26.739 3.942
19 The cost of poor quality results in long- term loss of 
sales, customers, and competitive advantages. 46 78.80 20.390 3.006
20 The cost of not having good quality is much more 
than cost of having high quality (cost of quality) 46 84.78 23.850 3.517
21  The cost of failure correction is higher than failure 
prevention 46 83.70 24.277 3.579
22 The management tracks cost of having good quality 
and bad quality 46 45.65 28.04 4.134
23 The management continuously measures the cost of 
quality and return on quality 46 60.33 23.319 3.438
24 The company concentrate on failure prevention more 
than failure treatment 46 77.17 21.619 3.188
25 The benefits of having high quality are more than 
costs of having high quality. 46 76.63 21.345 3.147
 Cost of conformance and nonconformance 46 71.26 10.283 1.516
Table 5.7.b. One-Sample Test
Test Value = 60
t df Sig. (2-tailed) Mean 
Difference
95% Confidence 
Interval of the 
Difference
Lower Upper
COC and CONC 7.429 45 .00 11.264 8.209
9
14.317
The  mean  of  quality  cost  tracking  is  71.26,  which  is  an  acceptable  result.  By 
determining the score (60) as test value, the one sample T- Test revealed that results 
are significant (calculated (t) = 7.429> tabulated (t) = 1.645). So, these significant 
results indicate that there is an understanding to cost of poor quality, cost of good 
quality, and return on quality.
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5.6 Benefits of quality on cost, culture, productivity, 
performance, sales, and profits
This  part  of  the  questionnaire  was  designed  to  investigate  if  Palestinian 
pharmaceutical  companies'  middle  level  managements  are  aware  of  benefits  of 
implementing  effective  quality  management  systems  and  complying  with 
international regulations and standards. The statements of this part were designed to 
investigate if companies could reduce operational costs, staff conflicts, time, and 
defects. These statements were also, designed to investigate   if companies could 
increase productivity and efficiency,  encourage suggestions, increase sales due to 
customer satisfaction, and generate more profits.
Table (5.8.a): Benefits of Quality
The effective implementation ISO 9000 &14000 
certificates and complying with GMP requirements leads 
to:
N Mean St. 
Deviation
St. 
Error
26   Reducing staff conflicts 46 67.93 22.150 3.266
27  Enhancing more suggestions 46 79.89 16.347 2.410
28 Reducing wastage of materials 46 80.44 16.594 2.447
29  Shortening  delivery lead time 46 77.72 18.430 2.717
30  Increasing employees efficiency 46 75.54 20.062 2.958
31 Increasing quantity of production (Productivity) 46 77.72 17.661 2.604
32 Reducing operational costs 46 72.28 26.472 3.903
33  Increasing profits 46 68.48 24.964 3.681
34 Achieving customer satisfaction and more competitive  
advantages which creates customer loyalty. 46 79.35 21.281 3.138
35  By focusing on investment on designing programs to 
prevent or reduce errors or failure, the company can 
reduce the costs of correction, leading to decrease cost of 
quality. 46 76.09 23.545 3.471
36  High Returns on investment due to quality improvement 
and international standards and regulations achievements 
justify the company to focus on achieving higher quality. 46 78.80 16.639 2.453
QUALITY BENEFITS 46 75.84 12.238 1.804
The  above  table  shows  that  the  mean  of  the  eleven  statements  means  (Quality 
benefits) is (75.84) which are acceptable comparing with the tested value (60). This 
means that  the majority  of respondents agrees  or strongly agrees that  there  is  a 
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positive impact of quality in reducing cost, waste material, and staff conflict. There 
is also impact of quality in enhancing more suggestions, increasing sales, generating 
more profits, improving productivity and efficiency. By calculating the frequencies 
of the answers, the following results were obtained:
Table (5.8.b): Percentages of respondents' answers to statements (26 – 34)
Score ↓Cost ↓Time ↓Wastages ↓Conflict
Strongly Agree 34.78 30.44 34.78 15.22
Agree 34.78 52.17 52.18 54.35
Neutral 15.22 15.22 13.04 17.39
Disagree 15.22 2.17  13.04
Strongly 
disagree    
Figure 2:  Percentages of Respondents' answers to statements (26- 34)
Score ↑Profit
↑Employees' 
suggestions ↑Productivity ↑Efficiency ↑Customers
Strongly Agree 21.74 32.61 28.26 28.26 23.91
Agree 47.83 54.35 56.52 50 54.35
Neutral 13.04 13.04 13.04 17.39 15.22
Disagree 17.39  2.18 4.35 4.35
Strongly 
disagree     2.17
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5.7 Impact of quality on competitiveness 
The impact of quality on competitiveness was addressed by the bulk of statements 
(22  statements).  This  part  was  designed  to  investigate  if  companies  agree  that 
implementing  quality  management  systems  could  improve  their  competitive 
advantages.  The  statements  focused  on  customer  satisfaction,  and  the  effect  of 
customer satisfaction on sales and market share. 
 The majority of respondents agreed or strongly agreed that quality could improve 
the competitiveness of companies through customer satisfaction and loyalty, which 
consequently  reduces  customer  complaints  and  increases  sales.  The  majority  of 
respondents believed that their companies are trying to find the best way of serving 
customers,  through producing high quality products that  comply with customers 
needs.  Companies  are  also,  soliciting  customer  feedback,  which fosters  stronger 
relationships between customers and companies.
The mean of the results is about 75.4 which is acceptable, and testing the results 
using one sample T- Test revealed that there is a significant correlation between 
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quality and improving competitiveness, ( calculated (t) = 10.484 > tabulated (t) = 
1.645) at 95% confidence.
Table (5.9.a) Impact of quality on competitiveness
# Statement N Mean St. 
Deviation
St. Error
37 The company understands how the product and service 
attributes fulfill basic customer needs. 46 76.09 18.971 2.797
38 The company furnishes clear and complete information to 
customers to ensure that customers formulate accurate 
expectations of products. 46 75 19.00 2.802
39  The company provides easy access to customers who 
seek assistance, wish to comment, or wish to complain. 46 77.72 21.232 3.130
40  The company proactively follows up with customers to 
seek feedback for improvement on products. 46 76.09 16.630 2.452
41  Improvements in the quality of the company’s products 
over the past  years have been translated into stronger 
customer loyalty. 46 71.20 22.34042 3.294
42  The company regularly compares its customer 
satisfaction levels with those of competitors. 46 67.93 17.210 2.538
43  The company uses the comparative assessment of 
customer satisfaction levels in its continuous 
improvement process. 46 65.76 19.263 2.840
44 The company documents trends and current levels of 
customer satisfaction relative to competitors. 46 64.67 20.122 2.967
45  The company documents trends in gaining or losing 
customers from or to competitors. 46 63.04 17.272 2.546
46 The company documents trends in the market share of 
competitors. 46 60.87 20.851 3.074
47  The company evaluates and improves its processes for 
determining customers’ future requirements and 
expectations for current and future products. 46 69.02 15.078 2.223
48 Increasing sales with existing customers, as a result of 
customer loyalty 46 71.74 19.443 2.867
49  Improving quality helps gaining more new local 
customers 46 73.37 21.986 3.242
50 Improving quality leads to reducing customer complaints 46 83.15 15.85906 2.338
51  Improving quality  enhances communication with 
customers 46 82.06 14.590 2.151
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52 Improving quality making customers to feel more 
confident that they will receive products conforming to 
their requirements, which in turn results in higher 
customer satisfaction 46 79.89 17.175 2.532
53 By producing high quality products, the company image 
will be improved. 46 85.33 15.434 2.276
54  Improving quality adds more competitive advantages. 46 88.04 13.682 2.017
55 By improving the quality, the company can effectively 
compete and can gain new customers 46 86.41 15.551 2.293
56 The company has established a good reputation of the 
quality of its products. 46 83.15 16.712 2.464
57 My department's emphasis on quality has resulted in 
measurable improvement in customer satisfaction 46 77.17 18.125 2.672
58 My department constantly looks for better ways to serve 
its customers. 46 80.98 18.397 2.713
Impact of quality on competitiveness 46 75.4 9.959 1.468
Table (5.9.b): Percentages of degree of agreement for each statement (48- 51 & 53- 
55)
Impact Strongly 
Agree
Agree Neutral Disagree Strongly 
Disagree
↑ New Local Customers 23.91 54.35 15.22 4.35 2.17
Less customer 
complaints
39.14 56.52 2.17 2.17
Better communication 
with customers
34.78 58.70 6.52
Improved company 
image
47.83 45.65 6.52
effective competition 52.17 41.31 6.52
Good reputation of the 
products
43.48 45.65 10.87
measurable improvement 
in customer satisfaction
30.43 47.83 21.74
More Competitive 
advantages
54.35 43.48 2.17
Figure 3: Percentages of degree of agreement for each statement (48- 51 & 53- 55)
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5.8 Reasons for complying with international standards 
and regulations
In this part, the respondents were asked to rank the reasons that push companies to 
comply  with  international  standards,  requirements  and  regulations  according  to 
their importance in the respondents’ point of view. 
Table (5.10.a) Percentages of reasons for complying with international standards, 
regulations and requirements:
Importance Competition in 
Local Market
Competitio
n in Global 
Markets 
Cost 
Reduction
Productivity 
and Efficiency
Recognition Customer 
Loyalty
Most Imp 23.9 % 34.8 % 6.5 % 15.2 % 8.7 % 8.7 %
Second 45.7% 19.6 % 13 % 8.7 % 6.5 % 6.5 %
Third 15.2% 17.4 % 13 % 21.7 % 8.7 % 26.1 %
Fourth 6.5% 8.7 % 17.4 % 32.6 % 10.9 % 23.9 %
Fifth 8.7 % 4.3 % 21.7 % 17.4 % 28.3 % 19.6 %
Least Imp 15.2 % 28.3 % 4.3 % 37 % 15.2 %
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Figure 4: Percentages of the importance of reasons for QMSs Implementation.
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The  results  in  the  table  explained  that  34.8%  of  respondents  believe  that 
competition  in  global  markets  is  the  most  important  reason  for  companies  to 
comply with international standards and regulations, whereas, 15.2 % believe that 
competition in global markets has the least importance. The competition in local 
market  was  ranked  mainly  as  the  second  important  reason  (45.7  %).  Gaining 
customer loyalty had the highest percentage as the third important reason (26.1 %), 
Improving  productivity  and  efficiency  got  the  highest  percentage  as  the  fourth 
important reason (32.6 %), (28.3 %) of respondents ranked the recognition as the 
fourth important reason, and 37% of respondents ranked it as the least important 
reason for complying with international standards and regulations. Cost reduction 
didn't get a high score in the ranking, and if the percentages are gathered in two 
categories  (most  important  +  Second  important+  Third  important)  and  (Fourth 
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important + Fifth important + Least Important), the results will indicate that 67.4% 
of respondents believe that cost reduction is not the most, the second or the third 
important  reason to push companies  into complying  with international  standards 
and regulations. 28% of respondents ranked cost reduction as the least important 
reason.
  By calculating the mean of each factor or reason, competition in local market was 
ranked to be the most important reason, competition in global markets was placed 
as  second important  reason,  the  third  important  factor  was  considered  to  be 
improving productivity and efficiency, while, customer loyalty was ranked as fourth 
important, compared to cost reduction which was ranked as the fifth reason, and 
recognition was ranked as the least important reason.
Table (5.10.b).: Means of  the six reasons for implementing QMSs.
Listed Reasons Mean Rank
1 Competition in  local Market 2.30 1
2 Competition in global markets 2.74 2
3 Cost Reduction 4.2 5
4 Productivity and efficiency 3.41 3
5 Recognition 4.54 6
6 Customer loyalty 3.85 4
5.9 Hypothesis Testing  
5.9. 1. The main hypothesis testing
1 H01  :  There  is  no  correlation  between  quality  management  systems 
implementation in pharmaceutical companies and cost.
2 Ha1:  There  is  a  correlation  between  quality  management  systems 
implementation in pharmaceutical companies and cost. 
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3 H02:  There  is  no  correlation  between  quality  management  systems 
implementation in pharmaceutical companies and competitiveness.
4 Ha2:  There  is  a  correlation  between  quality  management  systems 
implementation in pharmaceutical companies and competitiveness.
The  two  hypotheses  were  tested  by  applying  the  independent  sample  t-test,  the 
output data were tested to determine whether the results are significant at the test 
level of 0.05 significance. 
-  The  first  stated  null  hypothesis  "There is  a  correlation  between  quality  
management  systems  implementation  and  cost  in  Palestinian  pharmaceutical  
companies" is rejected because the calculated (t) value is greater than the tabulated 
value at (.05 level of confidence).  Calculated (t) value = 8.779 > Tabulated (t) value 
= 1.645, and the results were significant (sig. (2-tailed) = 0.000). This means that the 
first  alternative hypothesis  is  accepted  which is  "There is  a correlation between  
quality management systems implementation and cost in Palestinian pharmaceutical  
companies", and this correlation states that the effective implementation of quality 
management systems leads to cost reduction.  
- The second null hypothesis was also, tested and the results revealed that the second 
null  hypothesis  was rejected,  because the calculated (t)  value is  greater  than the 
tabulated value at (.05 level and df 45).  Calculated (t) value = 10.484 > Tabulated 
Table (5.11): One-Sample Test
8.779 45 .000 15.83992 12.2058 19.4741Quality Benefit
t df Sig. (2-tailed)
Mean
Difference Lower Upper
95% Confidence
Interval of the
Difference
Test Value = 60
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(t) value = 1.645, and the results were significant (sig. (2-tailed) = .000). This means 
that the second null hypothesis is rejected which is "There is no correlation between  
quality  management  systems  implementation  and  competitiveness  in  Palestinian  
pharmaceutical companies", so, the second alternative hypothesis is accepted which 
is "There is a correlation between quality management systems implementation and 
competitiveness in Palestinian pharmaceutical companies". This correlation states 
that the effective implementation of quality management systems could improve the 
competitiveness of Palestinian pharmaceutical companies. 
 
5.9.2 The sub-hypothesis testing
There  were  three  sub-hypothesis  for  the  respondents,  Position,  Department,  and 
Company.
H01:  There  are  no  differences  between  respondents'  answers  from  the  four  
companies 
µC1 = µC2 = µC3 = µC4
Ha1: There are significant differences between respondents' answers from the four  
companies
µC1 # µC2 #µC3 # µC4
Table (5.12): One-Sample Test
10.484 45 .000 15.39526 12.4377 18.3528Quality Comp
t df Sig. (2-tailed)
Mean
Difference Lower Upper
95% Confidence
Interval of the
Difference
Test Value = 60
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H02: There are no differences between managers and supervisors' answers.
  µManager = µSupervisor
Ha2:  There  are  significant  differences  between  managers'  and  supervisors'  
answers.
  µManager # µSupervisor
H03:  There  are  no  differences  between  answers  of  respondents  from  different  
departments.
µProduction = µfinance = µsales and marketing = µQuality control = µR&D = µOthers
Ha3:  There  are  significant  differences  between  answers  of  respondents  from 
different departments.
µProduction #µfinance # µsales and marketing # µQuality control # µR&D # µOthers
The first null sub hypothesis was tested by using one way ANOVA test to measure 
if there are  differences between the four companies in answering the likert part of 
the questionnaire. The Table (5.13), shows that there are significant differences in 
the quality cost (sig. 0.03 < 0.05), and slight significance in both quality concept 
and  management  commitment  (Sig.  0.08)  and  cost  of  conformance  and 
nonconformance tracking (0.08) between the four companies. On the other hand, 
there  is  no significant  difference in  the quality  benefits  (0.134) and quality and 
competitiveness (0.97). This means that the null hypothesis is accepted in quality 
cost,  in quality concept and cost of conformance and non conformance tracking. 
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Where  as  the null  hypothesis  is  rejected  in  both  quality  benefits  and impact  of 
quality on competitiveness.  
Table (5.13): ANOVA (Company)
 df F Sig.
Quality Concept 45 2.453107 0.08 *
Quality Cost 45 5.377974 0.003**
COC & CONC 45 4.52225 0.08*
Quality Benefit 45 1.964628 0.134
Quality Comp 45 0.081437 0.97
The second null sub hypothesis was also tested by applying one way ANOVA. The 
table (5.14) shows that there are no significant differences between the respondents 
from the different departments, which mean that the null sub hypothesis is accepted.
Table (5.14): ANOVA (Department)
Variable df F Sig.
Quality Concept 45 2.056 0.091
Quality Cost 45 0.329 0.89
COC and CONC 45 1.980 0.10
Quality Benefit 45 1.471 0.22
Quality Comp 45 0.489 0.78
The third null sub hypothesis was tested by applying the independent sample test. 
Table,  (5.15) shows that  there  are  significant  differences  between managers  and 
supervisors  in  answering  the  statements  on  quality  concept  and  management 
commitment (0.05). On the other hand there are no significant differences in the 
other  four  factors,  quality  cost,  quality  benefits,  cost  of  conformance  and  non 
conformance tracking, and impact of quality on competitiveness. This means that 
the third null sub hypothesis is rejected for the quality concept and management 
commitment for improving quality, yet, it is accepted in the remaining variables.  
Table (5.15): Independent Samples Test (Position)
df F Sig. t Sig. (2-tailed)
Quality Concept 44 8.553 0.005 2.015 0.050
Quality Cost 44 4.199 0.046 -0.154 0.878
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COC and CONC 44 0.023 0.880 -0.563 0.576
Quality Benefit 44 0.285 0.596 -0.258 0.798
Quality Comp 44 2.098 0.155 1.348 0.185
For the third part of the questionnaire (ordinal scale), one way ANOVA was applied 
to test the first and third null sub hypothesis. 
   For the first sub hypothesis the table (5.16), indicates that there are no significant 
differences between the four companies in ranking the reasons for complying with 
international standards and regulations. This means that the null sub hypothesis was 
accepted at a significant level 0.05. 
µC1 = µC2 = µC3 = µC4
Table (5.16); Differences in ranking the reasons of complying with international 
standards (Companies). 
Reason Mean df F Sig. Rank
Competition in  local Market 2.30 45 0.942 0.429 1
Competition in global markets 2.74 45 0.794 0.504 2
Cost Reduction 4.20 45 1.127 0.349 5
Productivity and efficiency 3.41 45 0.904 0.447 3
Recognition 4.54 45 0.037 0.99 6
customer loyalty 3.85 45 0.24 0.868 4
As illustrated in Table (5.17), the third null sub hypothesis was retained, at 0.05 
level of confidence, for all the six reasons which mean that there are no significant 
differences  between  respondents  from  different  departments  in  Palestinian 
pharmaceutical companies in ranking the reasons for complying with international 
standards and regulations.
µProduction = µfinance = µsales and marketing = µQuality control = µR&D = µOthers
Table (5.17) the differences between pharmaceutical departments in ranking reasons 
of complying with international standards.
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Reason Mean df F Sig. Rank
Competition in  local Market 2.30 45 0.786 0.566 1
Competition in global markets 2.74 45 0.114 0.989 2
Cost Reduction 4.20 45 1.042 0.406 5
Productivity and efficiency 3.41 45 0.365 0.870 3
Recognition 4.54 45 1.647 0.170 6
customer loyalty 3.85 45 1.096 0.38 4
 U-  test  was  applied  to  test  the  second  sub  null  hypothesis.  The  U-  test  is 
nonparametric  test  and  Mann-  Whitney  U  was  used  at  (0.05)  significance  to 
examine  whether  there  is  a  significant  difference  between  managers  and 
supervisors' answers. The Mann- Whitney U- test is a popular test that can be used 
for testing the differences between rankings of two independent groups. Based on 
the U value and the significant level of 0.05, the existing differences for each of the 
stated  reasons  for  complying  with  international  standards  and  regulations  were 
determined and reported. 
  As illustrated in Table (5.18), the U test indicates that the second stated null sub 
hypothesis “There is no difference between managers and supervisors" is accepted 
at a significant level of 0.05 or less for all the six factors.  
µManager = µSupervisor
Table  (5.18);  The  differences  between  positions  in  ranking  the  reasons  of 
complying with international standards.
Listed Reasons Mann- Whitney U Significant at 0.05
1 Competition in  local Market 174 0.145566
2 Competition in global markets 225.5 0.86575
3 Cost Reduction 203.5 0.487427
4 Productivity and efficiency 179 0.197423
5 Recognition 231 0.97084
6 customer loyalty 176.5 0.179819
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5.10 Correlation between results  
The aim of measuring this correlation was to investigate if there is a correlation 
between the five factors and in specific, the correlation between the quality concept 
and the other four factors. The results showed that there are significant correlations 
between  four  of  the  variables,  Quality  concept,  cost  of  conformance  and  non 
conformance tracking, benefits of quality, and finally quality competitiveness. Also, 
the  results  didn't  show  a  strong  correlation  between  quality  cost  related  to 
employees' resistance and any other factor. The table (5.19), shows that there is a 
significant correlation between quality concept and quality benefits ( p value= 0.557 
at sig.(2-tailed) = 0.000), quality concept and quality competitiveness (p value = .
656 at sig. (2- tailed) = 0.00). On the other hand there is a weak correlation between 
quality concept and cost of quality ( p value = 0.022 at sig. (2- tailed) = 0.887), and 
a  weak  correlation  between  quality  concept  and   cost  of  conformance  and  non 
conformance tracking (p value = 0.205 at  sig.  (2- tailed)= 0.172).  These results 
show that the concept of quality and management commitment are well understood 
and clear for employees, but tracking and measuring the costs are not well adapted 
or understood. These findings may be logical if they will be matched with the third 
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part of the questionnaire, in which the cost reduction was among the least reasons 
that  force  companies  to  implement  effective  quality  management  systems  and 
comply with international standards and regulations such as ISO or cGMP.
  Benefits  of  quality  and impact  of  quality  on competitiveness  have significant 
correlation between each others (p value = 0.430 at 0.01 level (2- tailed) = 0.003). 
Also, both of them have significant correlation with cost of conformance and non 
conformance tracking and quality concept at 0.01 levels (2- tailed).
Table (5.19): Correlation between the five variables:
Quality 
Benefits
Quality and 
Competitiveness
Cost of 
Quality
COC & CONC Quality 
Concept
Quality Benefits
 Pearson Correlation
                             Sig. (2-tailed)
                             N 
1
.
46
.430**
.003
46
.999
.000
46
.436**
.002
46
.557**
.000
46
Quality and Competitiveness Pearson 
Correlation
                             Sig. (2-tailed)
                             N
.430**
.003
46
1
.
46
.173
.249
46
.314*
.033
46
.656**
.000
46
Cost of Quality
Pearson Correlation
                             Sig. (2-tailed)
                             N
.000
.999
46
.173
.249
46
1
.
46
.016
.915
46
.022
.887
46
COC & CONC
Pearson Correlation
                             Sig. (2-tailed)
                             N
.436**
.002
46
.314*
.033
46
.016
.915
46
1
.
46
.205
.172
46
Quality Concept
Pearson Correlation
                             Sig. (2-tailed)
                             N
.557
.000
46
.665
.000
46
.022
.887
46
.205
.172
46
1
.
46
**. Correlation is significant at the 0.01 level (2-tailed).
*. Correlation is significant at the 0.05 level (2-tailed).
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5.11 Findings of the Interviews  
5.11.1 Findings of top management interviews.
The interviews  with top  managements  of  pharmaceuticals  were focusing on the 
impact of quality on cost and competitiveness. All general managers believe that 
quality leads to cost reduction. Companies have statistics and figures proving the 
benefits  of  quality  improvement.  This  includes,  but  not  limited  to,  improving 
productivity, reducing defects, recall batches, rejected batches, and generating more 
sales and profits.  Yet, they don't usually use these statistics as a strong point to 
continue improving quality or they don't deal with quality improvement as a power 
for  cost  reduction.  However,  the  impact  of  quality  improvement  might  not  be 
clearly felt due to the small size of the Palestinian market. So, it was clear that top 
management  don't  take  into  consideration  the  impact  of  quality  management 
systems on cost  reduction.  The data obtained from companies  clearly show that 
there is a positive impact of quality improvement on cost reduction and improving 
competitiveness and these findings comply with the findings of the questionnaire. 
The following tables  summarize some components  of costs  and how companies 
could reduce them through quality management systems implementations.  
Table 5.20; Impact of quality in Company 1 
Item 2000 2001 2002 2003 2004
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Productivity (%) + 3% + 4% + 22% + 24% + 16
Rework Rate - 12% 11% 7% 5%
Recall Batches 4 5 3 2
Rejected Batches 12 8 6 5
Actual Yield 93% 93% 92% 91%
Sales (%) + 7.14 - 6.67 + 2.9 + 33.33
Table 5.21; Impact of quality in Company 2 
Item 2000 2001 2002 2003 2004
Productivity (%) 88-90 90-92.5 90-94 >94 95-98
Defect Rate 10-12% 7-10 6-10 ~6 2-5
Rework Rate 8 8 6 5 2
Recall Batches 4 0 0 0 1
Rejected Batches 2 0 0 0 0
Actual Yield 88-90 90-92.5 90-94 >94 95-98
Accountability 95 95 97 98.5 99.5
Sales (%) + 9.6 - 9.2 + 33.1 + 19.3
Table 5.22; Impact of quality in Company 3 
* because of removing production equipments to the new building buildings
* Due to continuous curfew
Table 5.23; Impact of quality in Company 4 
Item 2000 2001 2002 2003 2004
Productivity (%) + - 3% + 13% + 1% + 2%
Defect Rate 3.99% 3.8 % 3.72 % 3.26% 2.96%
Rework Rate
Recall Batches - - - - -
Rejected 
Batches
5 10 2 2 5
Actual Yield 96.01% 96.20% 96.28% 96.73 % 97.04%
Accountability 98.01 % 98.2 % 98.6 % 99% 99.2%
Sales (%) + 6.7 - 11.9 + 27.13 33.76 NA
Item 2000 2001 2002 2003 2004
Productivity (%) 12+ 19+ -6*
Defect Rate 1% .55 1.3** .11 1%
Rework Rate NA
Recall Batches 0 0 0 2 0
Rejected Batches 0 0 0 0 0
Actual Yield
Accountability 96.1 96.6 94.4* 96.7
Sales (%) - 0.06 +3.4 - 2.4 + 28.04 NA
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Table (5.21): The % of non-conformance (Recalled) Batches (1982 – 2004)
1982- 1985 1995 1996 1997 1998 2002 2003 2004
% of Recall 
Batches
40% 6.3% 14.8% 3.3% 2.2% 2.5% 2% 0.9%
Source: MOH, 2004
The previous tables show that there is general improvement in cost reduction and 
productivity  improvement,  but  there  are  some  differences  in  the  results  or 
percentages and types of improvements between the four companies. This depends 
on each company culture, policies, and costs calculation procedures.  There are also, 
differences in sales improvement, which may related to type of products, sales and 
marketing policies,  the differences in images of the companies. 
When general managers were asked about reasons for investment in quality, there 
answers were generally similar. They are committed for improving quality in order 
to face the sever competition in local market and to meet requirements of expanding 
globally. One of the respondents said that "quality is a must", and what he meant by 
this is in order to compete specially in the global markets; companies have to get 
international standards and (GMP) certificates.
  As  mentioned  in  the  introduction,  none  of  the  Palestinian  pharmaceutical 
companies could achieve the GMP certificate. The GMP certificate is required by 
the  majority  of  the  world  countries  as  a  condition  to  allow  for  the  flow  for 
companies' pharmaceutical products. Getting GMP certificate will help companies 
to export and compete globally, or at least this certificate will help them export to 
neighboring Arab countries. About the reasons of not having GMP certificates tell 
now, the top managements mentioned many reasons such as:
- Non ending rules and requirements
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- Lack of cooperation from external auditors
- Problems related to buildings
- Financial problems.
- Validation requirements are the most constraints. Validation is one of the most 
important requirements and requires huge investments in man, machines, buildings, 
and process. Validation simply is the establishment of documented evidence that a 
system does what it is supposed to do. Other definitions also exist, e.g. that given in 
the  guidelines  on  GMP  for  pharmaceutical  products.  Unlike  many  other 
requirements of GMP, validation in itself does not improve processes, it can only 
confirm that the process has been properly developed and is under control. Ideally, 
any development  activity  in the  later  stages  should be finalized  by a  validation 
phase.
-  Lack  of  support  and  help  from the  Palestinian  National  Authority,  specially, 
Ministry of Health and Ministry of National Economy. These responsible ministries 
didn't  promote Palestinian pharmaceutical  industry in the Arab countries,  adding 
more to the difficulties of Palestinian pharmaceutical companies that do not have a 
Palestinian GMP to start with.
-  All  companies'  buildings  were established before trying  to  comply with GMP 
requirements. When managements of these companies decided to comply with the 
international standards and regulations, they had to redesign the buildings or build 
new buildings which required much more investment that consumed a lot of time 
and efforts. 
    When they were asked about the estimated time to get GMP certificate,  the 
answers  varied  from  two  years  to  five  years.  Referring  to  the  remaining 
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requirements for GMP certificate, all of them believe that they are implementing 
most of GMP requirements and there is no long gap to achieve the certificate. They 
believe that the major gap is the validation, and no one of these companies could 
achieve that.
5.11.2 Interviews with pharmaceutical industry Experts 
The interviews with the experts focused on their assessments or evaluation of the 
Palestinian pharmaceutical industry situation related to quality. The feedback was 
generally positive. All interviewed experts believed that Palestinian pharmaceutical 
companies worked well on quality improvement and they have strong commitment 
for improving quality and getting the GMP certificate.  
When the  director  of  quality  control  and registration  department  in  Ministry  of 
Health  was  asked  about  the  quality  improvement  levels  of  Palestinian 
pharmaceuticals,  he  answered  that  Palestinian  pharmaceutical  companies  could 
positively  improve  the  quality,  and  they passed a  lot  of  important  steps  toward 
achieving  the  certificate  of  GMP,  which  will  enable  them  to  export  to  many 
countries all over the world. However, he believes that Palestinian pharmaceutical 
companies  need  more  effort  to  achieve  this  goal.  The  major  problem  for 
pharmaceutical companies is the validation which is one of the main requirements 
for GMP certificate. When the director was asked about the reason of not offering 
Palestinian  GMP,  he  answered  that  having  a  Palestinian  GMP  will  not  add 
advantage for Palestinian pharmaceutical companies, as, that majority of countries 
don't  ask  for  national  requirements  certificate,  and  they  focus  on  GMP  as 
international standards and regulations.
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Referring to the failed items or batches, the experts agree that the recall batches or 
items  were sharply decreased  (from the year  1982 to  the  year  2004)  ,see table  
(5.20), as a result of quality improvement, and they believe that these failures cost 
companies a lot of money, and reducing the number of  failed items has a positive 
impact on cost reduction. Moreover, experts believe that the percentage of products 
with conformance  to  international  requirements  is,  in  general,  similar  to  that  of 
multinational companies, with some exceptions. But, they believe that Palestinian 
pharmaceutical companies still have a long way to go before achieving the GMP 
certificate. According to the director of registration and quality control department 
in  the  Ministry  of  Health,  the  Palestinian  pharmaceutical  products  are  of  good 
quality and  equivalent to the best quality products of neighboring Arab countries, 
but the problem of not achieving GMP certificate is due to the fact that Palestinian 
pharmaceutical companies built their factories and started production (1969 – 1986) 
neglecting complying with standards, which means that buildings were not designed 
according to the requirements, so,  when they started their journey toward getting 
GMP certificates, they had to make many changes on the buildings and they had to 
build new buildings to comply with the requirements which cost a lot of money and 
time. Moreover, the most critical stage of getting GMP is the Validation which is 
expensive and too complex to be achieved.
  One of the interviewed persons believed that Palestinian pharmaceuticals have to 
invest  in  Human  Resources  through  training  programs  and  they  have  to  be 
convinced that training is not a cost but rather a worthwhile.
 The evaluation of the external ISO Auditor for the four companies was positive. He 
believes that the pharmaceutical companies could effectively improve their quality 
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which  positively  affects  their  competitiveness  and  productivity.  The  external 
auditor  believes  that  the  pharmaceutical  sector  could  win  many  advantages  of 
implementing  ISO  9000:2000  and  ISO  14000,  especially  that  many  of  ISO 
requirements are also, required by GMP, so, pharmaceutical companies could save 
time, money and efforts to comply with GMP requirements and they could by pass 
these  steps.  Moreover,  he  believes  that  they  could  win  more  competitive 
advantages, especially, that having ISO certificate was a condition for companies to 
compete for tenders offered by NGOs like Care International. But, he believes that 
tracking costs of each item is a difficult process in pharmaceuticals, because the 
production process of each item takes many steps which makes tracking the cost of 
each  step  very  complicated,  so,  pharmaceutical  companies  calculate  the  overall 
costs and productivity monthly, quarterly, or annually.  
5.12 Conclusion
This  chapter  summarizes  the  general  findings  of  the  survey  distributed,  to 
supervisors and managers, and findings of interviews with top level managements of 
Palestinian pharmaceuticals and few experts. Since the questionnaire was divided 
into five parts, questions related to benefits of quality and impact of quality parts 
were planned to measure the validity of the hypotheses and the questions of the 
other parts were used to support the validity of the hypothesis. Finally,  statistical 
analysis was conducting and hypotheses were tested.
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CHAPTER SIX
Conclusions and Recommendations
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6.1 Introduction
 One  of  the  basic  assumptions  about  a  quality  system  is  that  it  is  primarily  a 
management function and secondarily a technical function. It would then follow that 
the  senior  management  of  an  organization  should  play  a  leading  role  in  the 
development of a quality system. If senior management recognizes that the quality 
system will provide real benefit to the organization and to management itself, and 
communicates this message to the staff, there is a greater likelihood that the quality 
system will be successful.
 The role of senior management is one of the most significant factors in creating 
successful cultural change and policies. Employees can also become involved in the 
process and establish an emotional link with their responsibilities (London, 2005). 
As Hagen (1999) discussed,  when employees  become emotionally  involved with 
their work, they will invest more to pursue excellence and the required targets and 
deal with quality improvement as a norm. Without this leadership, the process lacks 
direction and momentum and the resulting policies are largely ignored by those who 
do not have an investment in their success. 
  The  implementation  of  quality  management  systems  should  be  part  of 
comprehensive strategic plans, and the cost benefit  analysis  of improving quality 
should be done to achieve optimal benefits of this implementation. Thus, tracking 
cost of conformance and cost of non-conformance is required to justify the journey 
of  quality.  Customer  focus  which  leads  to  customer  involvement  in  the  quality 
improvement process will definitely lead to customer satisfaction and competitive 
advantage improvement. 
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    To assess the perception of the above mentioned factors needed for successful 
quality  management  systems  implementation,  this  study aimed to investigate  the 
understanding  of  quality  concept  and  management  commitment  for  improving 
quality, cost of quality related to employees resistance, and then to investigate the 
impact  of  quality  on  both  cost  and  competitiveness.  The  study  was  directed  to 
managers  and  supervisors  of  four  Palestinian  pharmaceutical  companies,  Jordan 
chemical  Laboratory-  Beit  Jala,  Jerusalem  pharmaceutical  company-  AlBereh, 
Birzeit  pharmaceutical  company-  Birzeit  /  Ramallah,  and Pharmacare-  Ramallah. 
The study tried to do these investigations using a questionnaire composed of three 
parts. The main part for the investigation was part two, which was the likert scale. It 
included 58 statements to be later collected and classified into five variables, quality 
concept and management commitment for improving quality, Cost of quality related 
to employees resistance, quality cost tracking procedures, Benefits of quality, and 
finally impact of quality on competitiveness.
  Part three of the questionnaire was designed to investigate the main reasons for 
pharmaceutical  companies  to  seek  implementing  effective  quality  management 
systems and complying with international standards and regulations. This part was 
designed as ordinal scale, in which respondents were asked to rank the reasons of 
implementing effective quality management system according to their importance.
  To gain more information about the pharmaceutical industry situation, interviews 
were conducted with many experts in the pharmaceutical industry. Interviews were 
also,  conducted  with  top  managements  of  the  four  targeted  pharmaceutical 
companies to gain further information about the core subject of the study.
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  Finally, the study aimed to investigate the concept of quality management and how 
companies could benefit of implementing quality management systems regarding to 
cost and competitiveness. But the study didn't try to track every item of operation 
costs and how companies could improve the quality to reach minimum cost. This 
was because of lack of accurate data provided by companies and due to the fact that 
companies don't use cost of quality systems to track the cost in every step.  
6.2 Conclusion
The study is a descriptive and the impact of quality on cost was investigated 
from the perspective of companies' manages and supervisors, and by using data 
from  companies  about  some  items  that  could  companies  improved  through 
quality  improvement.  These  items  are  scrap rate,  rework,  productivity,  recall 
batches,  rejected batches,  defect  rate,  accountability,  sales,  and market  share. 
These measurements were used before as indicators of impact of quality on cost 
or business performance by many researchers, like, (Deming, (1994); Imberman 
and DeForest (1995); Rowley and Sneyd, 1996;  Leung, and Chan,(1999); etc..  ) 
.
The conclusion would go over the main points illustrated in the previous chapters, 
by summarizing the foremost issues illustrating the concept of quality, management 
commitment  for  improving  quality,  and  impact  of  quality  on  both  cost  and 
competitiveness. The following issues were investigated:
- The quality concept and management commitment  for improving quality
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- Cost of quality related to employees resistance
- Benefits of quality
- Cost of conformance and Cost of nonconformance concept
- Impact of quality on competitiveness.
- The reasons of seeking to implement effective quality management systems 
and complying with international standards and regulations.
  The principle findings of the study include the following:
1. Quality  offers  organizations  significant  opportunities  for 
improvement,  including  reduced  costs,  increased  sales,  better 
performance to schedule, and more satisfied customers. A successful 
quality system does more than ensuring the quality of products and 
services; it drives vigorous operations and leads to a healthy bottom 
line. 
2. The concept of quality is well understood by the four pharmaceutical 
companies.  
3. In  general,  the  managements  of  the pharmaceutical  companies  are 
committed to improving quality,  and the quality is taken seriously. 
More than 91% of respondents strongly agree or agree that quality 
improvement process is considered as important priority. The middle 
level managements are actively involved in the quality improvement. 
This was clear from respondents' answers to questionnaire, through 
the  interviews,  and  through  reviewing  some  publications  about 
quality.
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4. The cost of quality: Palestinian pharmaceutical companies can spend 
money on quality by investing in good quality or by paying for poor 
quality. Successful ones invest in good quality because they know it 
costs much less over the long run. Respondents agree that preventing 
failures can save more money than having poor quality. Generally, as 
the costs dedicated to achieving good quality increase, the costs of 
poor quality decrease.
5. The cost of quality related to employees'  resistance: Manufacturing 
personnel believed that they would be overburdened with work and 
thus did their best to defeat the improvement scheme. While some 
managers  were  supportive  in  explaining  the  importance  of  the 
initiative,  it  was  ineffective  in  assisting  in  implementation.  This 
resistance  was  due  in  part  to  the  lack  of  top  management 
commitment, and also due to the lack of training and understanding 
of how the quality system would benefit the organization. People will 
accept  or  reject  change  depending  on  how the  change  will  affect 
them. A strategy that  convinces employees  is  needed to overcome 
this hurdle through emphasis on teamwork, brainstorming sessions, 
and consistent meetings. Employees’ participation and cooperation in 
the improvement programs must be recognized and encouraged for 
effective implementation of the improvement program (Bhuiyan and 
Alam, 2005). This concept was not easy to be investigated. There was 
no  clear  direction  for  the  related  questions.  This  was  clear  from 
answering the three related statements in the questionnaire, in which 
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the  number  of  respondents  who  answered  (Neutral  or  nor  agree 
neither disagree) were high. But in general, there are employees still 
believing  that  implementing  effective  quality  management  systems 
may  increase  time  and  reduce  productivity,  especially  in 
documentation, auditing, and testing processes.
6. Benefits  of  quality:  It  was  clear  that  implementing  quality 
management systems and complying with international standards and 
regulations has many advantages and benefits for the company, such 
as, staff conflict reduction, waste time reduction, defects reduction, 
scrap  rate  reduction,  reworks  reduction,   recall  items  reduction, 
improving  productivity  and  efficiency,  customer  satisfaction  and 
loyalty, increasing sales, and gaining more profits. Though research 
into the relationship between quality and profitability is inconclusive, 
proves  that  long-term investments  in  quality  lead  to  greater 
profitability through increases in market share, greater productivity, 
and lower costs. Theses results are complying with many previous 
studies results in pharmaceutical industry and other industries, such 
as  results  obtained  by  (Rowley  and  Sneyd,  1996).  An  additional 
benefit to learning and applying quality practices is that, in doing so, 
employees  gain  valuable  knowledge  and  skills  desired  by  other 
quality-minded  organizations  in  the  job  market,  which  leads  to 
improving employees efficiency. The results of the study showed that 
majority of respondents agrees that their efficiency was improved by 
improving quality (Mean= 75.45). 
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         The historical data obtained from the four companies, show that, the positive 
impact of quality may not clear or significant especially in items related to costs, 
this  may be  due  to  two facts.  First,  companies  are  focusing  on  production  and 
complying  with  international  standards  more  than  calculating  the  cost  of 
conformance and non conformance.  Second, companies are, in general, improving 
quality, through complying with international standards and producing according to 
international regulations, in order to improve their competitive advantages locally 
and globally,  and to be able  to  export  their  products.  According  to competitive 
advantage  improvement,  the  previous  literature  show  that  there  is  positive 
improvement of the companies' images, but tell now, the image about Palestinian 
pharmaceutical industry need a lot of efforts to be improved. 
7. Quality improvement and Productivity Relationships:  Perhaps the most important 
quality cost relationship is the one between quality and productivity. Productivity is 
the ratio of output to input, so any decrease in the amount of input needed to get the 
same  amount  of  output  increases  productivity.  Improving  quality  by  reducing 
defects, scrap, and rework will increase good output and reduce inputs. In this study, 
it was clear that majority of respondents believes that improving quality has positive 
impact  on  productivity  improvements  (mean  =  77.75).   The  overall  benefits  of 
quality management systems implementations were also approved by many studies. 
Lee, Leung, and Chan,(1999),  conducted a  survey  about the impact of ISO 9000 
certifications  and  they  concluded  that  certified   companies  are  able  to  derive  a 
certain  degree  of  benefits  from  the  standard   in  construction,  service  and 
manufacturing firms as  summarized in Table (6.1)
124
Table (6.1) Benefits of ISO certification
Manufacturing Service Construction All 
companies 
Clearer Work Procedure 99% 95% 96 % 96%
Improved quality of product 88% 92 % 85 % 88%
Improved team spirit 89% 86% 63% 77%
Better control of subcontractors 73% 79% 68% 73%
Increased efficiency 68% 71% 58% 65 %
Less customer complaint 61% 73% 54% 62%
Source: Lee, Leung, and Chan,(1999)
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 Adapted from: American Society for quality (quality 101)
↑ Quality:
Better Products and Services
Improved Process
↑ Products Quality
Reduced Scrap
Improved customer response  time
↑ Process Quality
Reduced rework
Elimination of in- process inspection
↑Customer Satisfaction
Compete with Value
↓Price
Compete with price
↑ Productivity:
decreased cycle time
Elimination of setup time
↑ Market 
Share
↓ Cost
- ↑ opportunity for 
profits
↑ 
Profits
QUALITY'S CONTRIBUTION TO PROFITABILITY
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8. Quality cost tracking process (Cost of conformance and cost of non 
conformance) Concept: the price of conformance is the cost of training, 
testing, auditing, and documentation. But the price of non conformance 
or  price  of  failure  (external  or  internal),  which  includes  the  price  of 
defects,  scrap,  rework,  recall  batches,  less productivity and efficiency, 
and  customer  complaints  and  dissatisfaction  which  leads  to  customer 
loss.  The  price  of  non  conformance  includes  cost  increase  and  sales 
decrease, which leads to profit decrease. 
Cost  of  Quality  (COQ)  =  Price  of  Conformance  (POC)  +  Price  of 
Nonconformance (PONC).  
           The results showed that companies understand the concept of quality costing, 
but they didn't use effective quality costing systems, however, recently, three of the 
four companies started implementing a computerized system to measure availability, 
performance, and quality.  This may help companies to track cost of conformance 
and  non  conformance.  Companies  started  seriously  focusing  on  training, 
documentation and inspection, which indicates that they concentrate on the cost of 
conformance. This means that managements know that preventing errors costs less 
than correcting them, and will have better returns than correction, but they don't use 
this fact to convince employees to operate efficiently.  However, they don't try to 
build the relation between investment in quality and the return on this investment, or 
at least the study couldn’t establish the opposite of this finding. These results are 
similar  to many results  of literature  who found that  majority of companies  don't 
track cost of quality. Sower, and Quarles, (2003), found that only about one third of 
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organizations in a sample of (2507 firms) systematically track quality costs. The 
principle  reasons  for  not  tracking  COQ  were  identified  as  lack  of  management 
support  or  absence  of  management  interest  in  tracking  such  costs,  company 
economic conditions or status contributed to the lack of cost of quality tracking, 
Lack of knowledge of how to track the cost of quality and  the benefits of a COQ 
program, lack of adequate accounting and computer systems necessary to track cost 
of quality,  and finally,  organizations did not see the benefit of COQ or that they 
needed to focus on areas which they perceive to be more important. 
The results are similar to the data reported by Imberman and DeForest (1995) about 
tracking Cost of Poor Quality (CPQ) such as rework, scrap), and comparing these 
costs to industry profits. Nearly all firms have such costs, but they seldom collect 
them for an overall  view. Eliminating cost is not easy.  For any cost reduction to 
occur, the company must first gain control of processes. It was also; clear from the 
collected data that there are differences in getting benefits of quality between the 
four companies.
9. Impact of quality on competitiveness: the study results show that implementing 
quality management systems can effectively improve the competitive advantages of 
the companies, and also can push companies to look for better ways of satisfying 
customers, this comply with one of the most important principles of  quality which 
is the customer focus. Marketing benefits of quality management include gaining 
new customers,  keeping existing customers,  using the standard as a  promotional 
tool, increasing market share, increasing growth in sales and improving customer 
satisfaction were classified as top priorities for the companies.
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10. Improving  competitiveness  and  reducing  costs  will  automatically 
increase sales and profits  and this  can be viewed in the following 
profit equation:
Profits =   Sales – Expenses 
By  improving  quality,  sales  will  increase  as  a  result  of  meeting 
customers' requirements which leads to customer satisfaction and gaining 
new  customers.  The  cost  reduction  occurring  as  a  result  of  quality 
improvement  will  reduce  the  total  expenses.  As  sales  increase  and 
expenses decrease, profits will increase. 
↑Customer satisfaction and 
loyalty
More new customers
Less complaints
Better relationships with 
customers
Good company image
Customer involvement in the 
quality improvement
↑Competitivenes
s
Quality and Competitiveness
Quality 
Improvement
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When respondents were asked to rank reasons of quality improvement, it 
was clear that facing sever competition locally or globally is the main 
stimulator  for  companies.  But  implementing  quality  management 
systems in order to manage and reduce operational or other costs was 
ranked as fifth of the six reasons, which means that companies don't track 
cost  and  benefit  to  check  if  investment  in  quality  can  have  positive 
impact on cost reduction. So, companies emphasis on competitiveness as 
a  key reason,  which means that  they are  focusing on the first  part  of 
profit equation which is sales increase. This may be because (1) firms do 
not usually know what costs can be attributed to a lack of quality control 
process, and (2) firms usually focus on improving performance through 
increasing sales instead of reducing costs. But, if companies emphasis on 
the  both  parts,  sales  increase  and expenses  reduction,  they  can  make 
better assessment of the impact of quality.
11. The results of the questionnaire and the interviews support that there 
is a positive impact of quality on cost reduction. The sharp decrease 
Quality
Competitiveness
Reduced Costs
More sales
Quality and Profitability
↑Profit
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of  recall  items  or  non  conformed  items  clearly  means  that 
improvement  of  quality  lead  to  decrease  of  failure  which  reduces 
costs.  Improvement  of  productivity  and efficiency and eliminating 
time, wastage, scrap, reworks, and defects also, reduce the costs.
12. The results,  also,  show that  sales  and market  share  of  Palestinian 
pharmaceuticals  are  positively  improved  and  there  is  an  annual 
increase in sales and market share.
13. Customers' perception also, positively improved from 1998 to 2000 
(Massar), which will help in improving Palestinian pharmaceuticals 
competitiveness.
14. Quality  improvement  and  investments  in  implementing  effective 
quality  management  systems  are  worthwhile.  This  is  clear  in  the 
impact  of quality and these results  are obtained by many previous 
studies like, Leung, Chan, and Lee, (1999), who conducted a survey 
of  some 500 ISO 9000 certified  companies,  has  been carried  out. 
Among  them,  more  than  65  per  cent  believe  that  ISO  9001 
certification is worthwhile, and more than 76 per cent believe that the 
cost of certification is inexpensive. They also found that concern for 
high costs is much less after initial certification.
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6.3 Recommendations
Based on the findings of this study, the following practical and policy implications 
may be formulated for Palestinian Pharmaceuticals and Ministry of Health:
6.3.1 Practical Implications for Palestinian Pharmaceutical 
Companies:
• Quality improvement has a good impact on cost reduction and competitive 
improvements,  these  correlations  may  push  companies  to  continue 
improving quality. Pharmaceutical companies can use the fact of benefits of 
quality as tools to convince their employees to improve quality of processes 
and products as self commitment for every employee and not because of the 
control  process and to  deal  with documentations,  auditing,  and testing as 
improvement tools not as tools for control and punishments.
•  Without  superior  quality,  operational  efficiency,  or  innovation,  the  only 
basis for international competition is price.  This may allow companies to 
win some contracts or some sales in the private market, but in the long run 
their products will always be cheaper. 
• It is strongly recommended that Palestinian pharmaceutical companies focus 
more  and  more  on  reaching international  quality  standards like  GMP 
certificates.  Having  GMP certificates  will  enable  companies  to  export  to 
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Arab  countries  and  other  countries  all  over  the  world,  which  may  help 
companies to expand and to use full capacity. 
•  To get GMP certificates, Palestinian pharmaceutical companies have to pass 
few  important  steps  and  one  of  the  most  important  and  critical  steps  is 
getting validations. To obtain validation, companies need to invest heavily in 
buildings,  manpower,  and  equipments,  which  cost  a  lot  of  money.  So, 
companies may act in two parallel plans, the first is increasing there market 
shares in local market which can generate better returns. Second, companies 
can plan for expanding globally and try to find potential markets for their 
products. 
• Cost and Benefit of quality:  By analyzing the cost and benefit of quality, 
companies  can  assess  the  effect  of  quality  improvement  on  the  cost, 
productivity,  and performance. Cost of quality tracking system advantages 
were summarized by Bottorff, (1997) as follows:
 
1. Quality data are more readily accepted because they are gathered and 
analyzed with the accounting department in a team environment. The 
quality  cost  data  can  be used in  an effort  to  be proactive,  and  to 
identify  causes  of  problems.  It  provides  a  methodology  for 
pinpointing improvement priorities. Once the causes are resolved, the 
defects do not occur and failure costs decrease.
2. The  COQ  system  aids  in  the  evaluation  of  capital  investment 
alternatives.
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3.  The COQ system helps justify and steer investments in prevention 
activities, which lowers quality costs. It also helps justify and steer 
other quality improvement efforts and investments.
4.  The  COQ system leads  to  the  development  of  a  more  advanced 
performance  measure  in  the  areas  of  customer  satisfaction, 
production and design to better target indirect quality costs.
5. Return on investment and sales are improved while reducing costs.
       Quality  costing  can  be  considered  as  a  measurement  of  a  company's 
performance with respect to the process by which a product is produced or a service 
delivered.  The  quality  cost  system  concept  can  also,  be  applied  to  improve 
productivity.  There  is  a  need  for  an  analytical  framework  that  explains  the 
relationship between quality cost components and quality. Once these relationships 
are defined and clearly understood, the ability of an organization to make decisions 
related to improving quality, reducing quality costs and increasing productivity will 
be substantially enhanced.
•  Specialization: To reduce competition between Palestinian pharmaceuticals, 
each company can specialize in a small number of product lines which also, 
help companies to focus on certain products and innovate in producing and 
promoting these items.  
• Palestinian companies have about 50% of the market share. Because they 
mainly, operate and produce for the local market they have opportunity to 
dominate the local market and increase their market share and percentage of 
coverage.
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• International and / or local Partnership: This may help companies to compete 
and  survive  in  the  extreme  global  competition  and  this  may  help  in 
investment in R&D.
• Investment in human resources: Companies need to invest more and more in 
employees by recruiting skillful staffs and training the existing staffs. The 
well qualified people can perform better and their productivity and efficiency 
can  be  improved;  this  also,  will  eliminate  failure  or  non  compliance. 
According  to,  McDonald,  (2003),  the  costs  associated  with  current  Good 
Manufacturing Practices (cGMP) noncompliance is skyrocketing.  Many of 
these noncompliance issues directly correlate to inadequate training. Firms 
need  to  focus  on  developing  a  training  strategy  to  tackle  cGMP  non-
compliance  head  on.  An effective  training  strategy  includes  teaching  the 
theory behind the practice, allowing for experience sharing during training, 
motivating learners to learn,  allocating the appropriate  amount  of training 
time,  creating  a  comfortable  learning  environment,  choosing  an  effective 
trainer,  and  evaluating  the  learning  experience.  By  implementing  these 
elements into an effective training strategy, pharmaceutical firms can greatly 
reduce the risks and high costs associated with non compliance to GMPs.
• Employees' involvement in the quality improvement is critical and is a must 
in  order  to  overcome  any  resistance  for  change  and  to  enhance  their 
commitment for improving quality and to understand that "Quality must be 
improved and cannot be controlled".  
• Pharmaceutical  companies  have to  convince customers  that  their  products 
are high quality products and to promote themselves as producers of high 
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quality products or as producers according to international regulations and 
standards  and they have to  try  changing local  customer  perception  about 
quality  level  of  Palestinian  pharmaceuticals.  This  may  be  through 
coordination with MOH and/ or any other institutions, or through the UPPM. 
Changing local customers' perception is critical for companies to compete. 
Changing customers' perceptions can be done in three levels of customers:
1.  Doctors:  They  are  the  main  target  customers  because  doctors  are  the 
decision  makers  of  selecting  the  medicine.  Positive  feedback  of  doctors 
about local  pharmaceuticals  can help in reputation and loyalty,  leading to 
better prescription and more sales.
2.  Pharmacists:  they  are  important  especially  in  selecting  over  the  counter 
drugs (OTC) and many patients  prefer  consulting pharmacists  and asking 
them for treatment without visiting doctors' clinics. In general, pharmacists 
believe  that  Palestinian pharmaceuticals  can compete mainly in  price and 
bonus, not in quality. So, it is recommended to change the sales policies and 
change the perception from bonus and price oriented to quality oriented.
3.   End users: End users of medicine have minor roles in selecting medicine 
but  some  times  they  influence  doctors  to  select  items  according  to  their 
origins, and according to Massar, (1997: 2000),(41%) patients  prefer using 
foreign or Israeli medicine more than Palestinian drugs, for quality reason. If 
companies  believe  that  they  are  producing  according  to  international 
standards and their products' safety and efficacy are guaranteed, so, it is a 
challenge for Palestinian pharmaceutical companies to prove this and try to 
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change the perception which believes that Palestinian pharmaceuticals have 
lower quality than foreign and Israeli products.
6.3.2 Policy Implications for Palestinian Ministry of Health:
To help both customers getting effective, safe, and high quality medicine and to 
help pharmaceutical  sector to  continue improving  quality which enables  it  to 
compete and survive, there are some policy implications for Ministry of health 
that could possibly be adopted. 
•  Promoting  Palestinian  pharmaceuticals,  regionally  and internationally,  as 
good quality products may help companies to compete and gain revenues. 
The additional revenues may help companies to continue investing in quality 
improvement. 
• The quality control department in MOH has to be reconstructed. This will 
help in having better controlled products.
•  Establish  a  technology  incubator  for  pharmaceutical  R&D:  Innovation 
creativity,  competition  and  quality  are  challenges  for  pharmaceutical 
industry  locally  and  globally  to  survive.  So,  technology  incubator  for 
pharmaceutical R&D will help to face these challenges.  
•  Establish a clear set of standards and regulations: This will help companies 
to implement these standards and regulations and to evaluate their situations 
and will also, help the sector to use the standards as corner stone for quality 
improvement.  
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•  Create a regulatory agency which can be used as a competitive advantage: 
The regulatory agency may help in creating positive image of the Palestinian 
pharmaceutical sector, because customers will feel more confidence that the 
products are controlled by authorized regulatory agency, and the quality is 
ensured. This will help in competition and customer loyalty.
• Continue efforts to open new markets through fair trade agreements: this will 
help  companies  to  realize  growth  plans  which  will  consequently  lead  to 
decrease the total cost.
•  Continue work to improve import/export abilities.
6.4. Recommendations to other studies
It  is  not  easy  to  decide  to  implement  Cost  of  Quality  systems  in  organizations, 
especially  pharmaceutical  organizations,  because  they  are  concentrating  on 
complying with international standards and regulations and aiming to increase sales 
and  profits,  which  minimizes  there  interest  in  tracking  cost  of  achieving  good 
quality products and/ or tracking the cost of having poor quality products. Therefore, 
the first recommendation is to show the importance of implementing this process. 
Secondly, in this study it was apparent that impact of implementing effective quality 
management  systems  and complying  with international  regulations  and standards 
was not easy to be investigated,  because it requires many details  either from the 
customer  perspective,  competitors'  situation,  or  performance  of  employees, 
equipments,  and  the  system as  a  whole.  Thirdly,  implementing  effective  quality 
management  system  is  heavily  dependent  on  the  contribution  of  key  people 
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concerned, senior management of the organization and their willingness to make it 
success,  since  this  technique  has  strategic  implications  on  the  organization 
implementing such a system. Fourth, bringing this study to an end at this stage is a 
waste of time and effort,  i.e.  pursue the recommendations and strictly implement 
them; continuously improve the level of quality in Palestinian pharmaceuticals; and 
make  quality  improvement  as  a  culture  change  agent  and  has  to  be  gradually 
integrated as part of bigger umbrella of change, a total quality management program, 
which  drives  efficiency,  effectiveness  and  continuous  measurement  for  superior 
competitiveness. Fifth, this study investigated the correlation between quality and 
cost by using a questionnaire distributed to companies'  managers and supervisors 
and interviews with the top level managements,  so, it  is recommended to search 
deeply in the items of costs that are affected by quality improvement. This may be 
done by tracking the cost per unit and assessing the changes of these costs to get 
more precise calculations and results.
Furthermore, it can be concluded that implementing quality management systems is 
a  powerful  tool  in  TQM and has  been used in  pharmaceutical  manufacturing  in 
many other countries. 
6.5. Contribution to the theoretical knowledge
This survey is a pioneer study in the field of pharmaceutical industry in Palestine or 
may be in the Middle East. This study stressed the management commitment for 
improving quality, continuous improvement of employees' participation, impact of 
quality improvement on cost and competitiveness. The data are provided by middle 
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management  research  and  analysis  and  the  top  management  and  other  experts 
interviews. This study is considered a pioneer especially in the process of translating 
impact of quality from qualitative perceptions and understanding of employees in to 
quantitative  measurements,  where it  would be precise  to  determine  what  exactly 
should be done to achieve the target of study, namely cost reduction and improving 
competitiveness in pharmaceutical industry.
6.6. Contribution to the practical knowledge
The  study  addressed  a  number  of  recommendations  to  both  Palestinian 
Pharmaceutical Companies and the Palestinian Ministry of Health (the authorized 
institute to control pharmaceutical  products' registration and quality in Palestine). 
For companies, the recommendations focused on how to improve the performance 
of  their  strategic  and  action  plans  to  eventually  achieve  a  level  of  customers’ 
satisfaction, and to positively change customer perception about products' quality, 
which  will  definitely  affect  their  competitiveness  and  share  in  the  local  market 
place. In addition to meeting their obligation towards the society when providing 
high  quality  products  and  to  cover  the  local  market  needs.  Moreover,  the  study 
recommended  companies  to  continue  their  efforts  toward  achieving  GMP 
certificates which enable them to export their products all over the world, and this 
will help them to compete in the global market and if they could export this will 
increase their production (mass production) and generate more profits. Finally, the 
study recommended companies to measure costs and benefits of quality which will 
justify companies to continue improving quality.
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The  recommendations  for  Ministry  of  Health  were  focused  on  how  to  help 
Palestinian  pharmaceutical  companies  achieving  international  standards  and 
regulation such as GMP, to promote Palestinian pharmaceuticals in Arabic countries 
and other global markets as high quality products and signing agreements with these 
countries to import Palestinian pharmaceuticals.  
If  both  companies  and  Ministry  of  Health  implement  some  or  all  these 
recommendations,  it  will  be  beneficial  for  companies'  achievements,  customer 
loyalty, and national economy.
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Appendices
Appendix - 1- 
Questionnaire Covering letter
Dear Manager / Supervisor:
   I am a student in the MBA program – Bir Zeit University and I am conducting a 
master  thesis  about  the  impact  of  quality  management  systems  on  cost  and 
competitiveness in Palestinian pharmaceutical companies. The purpose of the study 
is  to  investigate  the  relationship  between  effective  implementation  of  quality 
management systems (ISO 9000, ISO 14000, and GMP), cost and competitiveness, 
and  to  investigate  whether  the  companies  can  benefit  from having  high  quality 
products.
  It would be highly appreciate, if you would please spend a little of your precious 
time  and  answer  the  following  questionnaire,  assuring  you  that  all  information 
provided will be treated with utmost confidence and will never be used for any other 
purpose than this research. I am sure that any provided information will be valuable 
and will enrich my research.  
Thanking you in advance for your kind cooperation and assistance in completing 
this research.
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Sincerely:
Ziyad Abu Rob
Bir Zeit University
Appendix – 2-
Questionnaire
PART ONE
1. Position
1) Manager                   2) Supervisor
2. Department / Division
1) Production        2) Finance      3) Sales and Marketing    4) Quality Control/ 
Assurance             5) R& D     6) Others
PART TWO
Please choose the suitable score of each of the following statements:
1) Strongly Agree      2) Agree     3) Neither agree nor disagree   4) Disagree     5) Strongly Disagree
Statement 1 2 3 4 5
QUALITY CONCEPT AND ORGANIZATION COMMITMENT FOR 
QUALITY
1- Employees in my department are adequately informed about the quality 
standards that apply to their jobs.
1 2 3 4 5
2- Employees in my department are adequately informed about the quality 
objectives of our department.
1 2 3 4 5
3- We have the technical and managerial skills necessary to measure the quality 
of work.
1 2 3 4 5
4- The quality improvement process is considered an important priority by Senior 
Management
1 2 3 4 5
5- The quality improvement process is considered an important priority b y 
Myself
1 2 3 4 5
6- The  quality improvement process is considered an important priority b y My 
department employees
1 2 3 4 5
7- Too much emphasis is placed upon quality of work produced rather than its 
quantity.
1 2 3 4 5
8- Quality improvement is viewed as a long term commitment, not to be 
compromised by short- term financial goals.
1 2 3 4 5
9- My department's emphasis on quality has resulted in measurable improvement 
in our products and services
1 2 3 4 5
10- Management commitment to quality is apparent in what we do on day-to- day 
basis.
1 2 3 4 5
11- The top management and the middle level management are implementing 
programs and processes for quality improvement
1 2 3 4 5
12- The top management and the middle level management are providing tools and 1 2 3 4 5
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resources required for quality improvement.
13- The company feels more confidence that the company’s products meet 
relevant regulatory requirements.
1 2 3 4 5
14- The company often sacrifices the quality of products in order to cut costs. 1 2 3 4 5
COST OF  QUALITY
ISO 9000, and 14000 certificates and complying with GMP requirements 
increase costs as follows.
15- Operating according to ISO and GMP requirements force employees to spend 
a lot of time on documentation and inspection which can be used for 
production.
1 2 3 4 5
16- The continuous concentration on the rules and requirements of ISO and GMP, 
causes employees to feel inconvenience, which affects there productivity and 
performance.
1 2 3 4 5
17- Some employees feel that a lot of steps used according to standards are not 
necessary, and they some times resist doing them.
1 2 3 4 5
COST OF QUALITY TRACKING 1 2 3 4 5
18- The cost of poor quality in short- term are due to scrap rate, rework, defects, 
etc. 
1 2 3 4 5
19- The cost of poor quality results in long- term loss of sales, customers, and 
competitive advantages.
1 2 3 4 5
20- The cost of not having good quality is much more than cost of having high 
quality (cost of quality)
1 2 3 4 5
21-  The cost of failure correction is higher than failure prevention
22- The management tracks cost of having good quality and bad quality
23- The management continuously measures the cost of quality and return on 
quality
24- The company concentrate on failure prevention more than failure treatment 1 2 3 4 5
25- The benefits of having high quality are more than costs of having  high quality. 1 2 3 4 5
BENEFITS OF QUALITY 
The effective implementation ISO 9000 &14000 certificates and complying with 
GMP requirements leads to:
26-   Reducing staff conflicts 1 2 3 4 5
27-  Enhancing more suggestions 1 2 3 4 5
28- Reducing wastage of materials 1 2 3 4 5
29-  Shortening delivery lead time 1 2 3 4 5
30-  Increasing employees efficiency 1 2 3 4 5
31- Increasing quantity of production (Productivity) 1 2 3 4 5
32- Reducing operational costs 1 2 3 4 5
33-  Increasing profits 1 2 3 4 5
34- Achieving customer satisfaction and more competitive advantages which 
creates customer loyalty.
1 2 3 4 5
35-  By focusing on investment on designing programs to prevent or reduce errors 
or failure, the company can reduce the costs of correction, leading to decrease 
cost of quality.
1 2 3 4 5
36-  High Returns on investment due to quality improvement and international 
standards and regulations achievements justify the company to focus on 
achieving higher quality.
1 2 3 4 5
157
Statement
IMPACT OF QUALITY ON COMPETITIVENESS
37- The company understands how the product and service attributes fulfill basic 
customer needs.
1 2 3 4 5
38- The company furnishes clear and complete information to customers to ensure 
that customers formulate accurate expectations of products.
1 2 3 4 5
39-  The company provides easy access to customers who seek assistance, wish to 
comment, or wish to complain.
1 2 3 4 5
40-  The company proactively follows up with customers to seek feedback for 
improvement on products.
1 2 3 4 5
41-  Improvements in the quality of the company’s products over the past  years 
have been translated into stronger customer loyalty.
1 2 3 4 5
42-  The company regularly compares its customer satisfaction levels with those 
of competitors.
1 2 3 4 5
43-  The company uses the comparative assessment of customer satisfaction 
levels in its continuous improvement process.
1 2 3 4 5
44- The company documents trends and current levels of customer satisfaction 
relative to competitors.
1 2 3 4 5
45-  The company documents trends in gaining or losing customers from or to 
competitors. 
1 2 3 4 5
46- The company documents trends in the market share of competitors. 1 2 3 4 5
1 2 3 4 5
47-  The company evaluates and improves its processes for determining 
customers’ future requirements and expectations for current and future 
products.
1 2 3 4 5
48- Increasing sales with existing customers, as a result of customer loyalty 1 2 3 4 5
49-  Improving quality helps gaining more new local customers 1 2 3 4 5
50- Improving quality leads to reducing customer complaints 1 2 3 4 5
51- . Improving quality  enhances communication with customers 1 2 3 4 5
52- Improving quality making customers to feel more confident that they will 
receive products conforming to their requirements, which in turn results in 
higher customer satisfaction
1 2 3 4 5
53- By producing high quality products, the company image will be improved. 1 2 3 4 5
54- . Improving quality adds more competitive advantages. 1 2 3 4 5
55- By improving the quality, the company can effectively compete and can gain 
new customers
1 2 3 4 5
56- The company has established a good reputation of the quality of its products. 1 2 3 4 5
57- My department's emphasis on quality has resulted in measurable improvement 
in customer satisfaction
1 2 3 4 5
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58- My department constantly looks for better ways to serve its customers. 1 2 3 4 5
PART THREE
Reasons for getting ISO 9000 and 14000 certificates and GMP requirements:
Please  rank  the  reasons  that  forced  the  company  to  get  ISO  certificates  and 
complying with GMP requirements according to the importance (number 1 is the 
most important and 6 is the least important)
Reason Importance
Competition in the local market
Competition in the global markets
Cost Reduction
Productivity and efficiency
Recognition 
Customer Loyalty
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Appendix – 3-
Interview questions to the top management of Palestinian 
pharmaceutical companies.
• What is the most important reason for implementing quality management 
systems and producing according to international regulations (GMP):
Reason Importance
Competition in the local market
Competition in the global markets
Cost Reduction
Customer Loyalty
Productivity and efficiency
Recognition 
Exporting Requirements
• Benefits of quality on operational costs:
Item % decrease or increase
 Defects reduction
Productivity
Time management improvement
Rework
Electrical consumption
Water Consumption
Employees performance (productivity and efficiency)
Recall Batches before introducing to the market (internal 
failure)
Recall Batches after introducing to the market (external 
failure)
• Impact of quality improvement on sales and competitiveness:
• How  can  the  company  use  the  benefits  of  quality  management  as  a 
competitive advantage?
• How  does  the  top  management  involve  employees  in  the  quality 
management system?
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•  How does the company overcome employees' resistance for change?
• No Palestinian pharmaceutical company has achieved Good Manufacturing 
Practices certificate (GMP), why? And where is the gap?
• What is the estimated time to have GMP certificate?
• What are the most important reasons for not having Palestinian GMP?
Reason Importance
Lack of experience and expertise
Lack of knowledge
Lack of needed budget
Lack of control
Benefits of complying with international requirements are better 
than complying with national requirements (in global market).
 
 
161
